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NSCLC. Protein kinase C (PKC), a family of serine/threonine kinases that are targets of phorbol ester/
diacylglycerol, has been shown to be involved in EGFR and KRAS signaling, indicating their importance in
lung cancer progression. In this thesis work, we established the requirement of PKCα and PKCε in the
malignancy of lung cancer in the context of EGFR and KRAS mutations. Using an isogenic model system,
we found NSCLC cells that are resistant to the EGFR-tyrosine kinase inhibitor erlotinib display remarkably
high levels of PKCα compared to the parental erlotinib sensitive cells. Inhibition of PKCα resulted in
sensitization to erlotinib treatment and loss of gene expression associated with mesenchymal phenotype.
Additionally, we showed that PKCα signaling controls activation of a key regulator of lung cancer
progression, NF-κΒ. PKCα depletion by RNA interference in lung cancer cells indeed attenuates IκΒα
phosphorylation, subsequent impairment of NF-κΒ translocation into the nucleus, and induction of NF-κΒ
target genes in response to interleukin 1 beta (IL-1β). Finally, in the context of KRAS mutation, we
presented evidence showing the requirement of PKCε signaling for the formation of KRAS-driven lung
tumors in vivo. Tumor formation in the double transgenic KRASG12D;PKCε-/- mice was remarkably
reduced compared to KRASG12D;PKCε+/+ mice. All together, this thesis work highlights the multiple roles
that PKC isozymes play in the initiation and progression of lung cancer, and suggests a potential
therapeutic role for PKCα and PKCε inhibitors for prevention and treatment of lung tumors.
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ABSTRACT
PKC ISOZYMES IN LUNG CANCER DEVELOPMENT AND THERAPY
RESISTANCE

Mahlet B. Abera

Marcelo G. Kazanietz, Ph.D.

Non-small cell lung cancer (NSCLC) is one of the major causes of cancer related
mortality worldwide and comprises the most frequent type of lung cancers. Oncogenic
alterations such as activating mutations in the epidermal growth factor receptor (EGFR)
and KRAS have been implicated in the pathogenesis of NSCLC. Protein kinase C (PKC),
a family of serine/threonine kinases that are targets of phorbol ester/diacylglycerol, has
been shown to be involved in EGFR and KRAS signaling, indicating their importance in
lung cancer progression. In this thesis work, we established the requirement of PKCα and
PKCε in the malignancy of lung cancer in the context of EGFR and KRAS mutations.
Using an isogenic model system, we found NSCLC cells that are resistant to the EGFRtyrosine kinase inhibitor erlotinib display remarkably high levels of PKCα compared to
the parental erlotinib sensitive cells. Inhibition of PKCα resulted in sensitization to
erlotinib treatment and loss of gene expression associated with mesenchymal phenotype.
Additionally, we showed that PKCα signaling controls activation of a key regulator of
lung cancer progression, NF-κΒ. PKCα depletion by RNA interference in lung cancer
iv

cells indeed attenuates IκΒα phosphorylation, subsequent impairment of NF-κΒ
translocation into the nucleus, and induction of NF-κΒ target genes in response to
interleukin 1 beta (IL-1β). Finally, in the context of KRAS mutation, we presented
evidence showing the requirement of PKCε signaling for the formation of KRAS-driven
lung tumors in vivo. Tumor formation in the double transgenic KRASG12D;PKCε-/- mice
was remarkably reduced compared to KRASG12D;PKCε+/+ mice. All together, this thesis
work highlights the multiple roles that PKC isozymes play in the initiation and
progression of lung cancer, and suggests a potential therapeutic role for PKCα and PKCε
inhibitors for prevention and treatment of lung tumors.
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CHAPTER 1: Introduction
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1.1 Lung cancer
Lung cancer is the largest contributor to new cancer diagnosis and cancer-related
death each year [57]. Most lung cancer patients have advanced disease at the time of
diagnosis, shortening the 5-year survival rate to only 10-15 %. On the basis of histology,
lung cancers are classified as small cell lung carcinoma (SCLC) and non-small cell lung
carcinoma (NSCLC). NSCLC comprises 80 % of lung cancer cases and is further subdivided into adenocarcinomas (50 %), squamous cell carcinoma (35 %) and large cell
carcinoma (15 %). Small cell lung carcinomas and squamous cell carcinomas arise from
the central compartments of the lung, while adenocarcinomas arise from the progenitor
cells of the bronchioles (Clara cells), alveolar type II cells, or from mucin producing cells
in the peripheral compartment of the lungs (Table 1.1) [24, 162].
Lung tumorigenesis involves a series of progressive pathological changes in the
mucosa membrane lining the respiratory tract. In squamous cell carcinoma development,
the bronchial epithelium undergoes a series of morphological changes that represent cell
transformation from normal into precursor lesions, including hyperplastic, metaplastic,
and dysplastic lesions. While hyperplasia and squamous metaplasia are considered
reversible changes, dysplastic lesions are most frequently associated with the
development of squamous cell lung carcinomas. Similarly, adenocarcinomas develop as a
result of transformation from premalignant precursor lesions to carcinoma in situ.
However, in the case of adenocarcinomas, the only known precursor lesion is atypical
adenomatous hyperplasia [62, 65, 205].
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Tumor
type
NSCLC

Tumor subtype

Incidence

Location

Adenocarcinoma

40 %

Squamous cell
carcinoma
Large cell carcinoma

25 %

Others/mixed

5 %

Outer edge of lungs, from mucus
producing cells
Central compartment, from cells that line
the airways
Any area of the lung
In the bronchi near the center of the
chest
Mixed

SCLC

15 %
15 %

Table 1.1 Histological classification of lung cancer
Lung cancer is commonly classified as small cell carcinoma (SCLC) and a heterogeneous
group of non-small cell carcinomas (NSCLC), which includes adenocarcinoma,
squamous cell carcinoma and large cell carcinoma. SCLCs arise in the central
compartment of the lungs, while NSCLCs commonly arise in the peripheral regions of
the lungs.
Tobacco smoke is the main cause of lung cancer with 80-90 % arising in cigarette
smokers. However, in spite of the exposure to carcinogens, only 10-15 % of heavy
smokers ultimately develop the disease, which reflects the role of genetic factors in
predisposing to lung cancer [20]. The concept of field of cancerization has been described
to elucidate the implication of tobacco smoke in cancer initiation. Exposure to tobacco
smoke creates injury in the airway epithelial cells leading to development of field of
cancerization with genetically and epigenetically altered cells. Field of cancerization
consists of tissue adjacent to neoplastic lesions that display normal histology, but harbors
molecular abnormalities similar to tumors [37]. There are three major theories describing
the origin of smoking-related field of cancerization in lung tumorigenesis. One, injury
due to cigarette smoke causes a single mutant epithelial cell clone that expands and
extends into the respiratory lining. Second, exposure to carcinogens in cigarette smoke
damages the entire airway tract and results in random genetic mutations in multiple areas
3

that arise from polyclonal tumor stem cells. The third theory is that once the tumor is
initiated, the cancer itself affects the surrounding tissue, contributing to alterations
including oncogenic activations, tumor suppressor gene (TSG) silencing, and widespread
loss of heterozygosity leading to malignancy [62, 113, 170].

Key genetic and epigenetic changes in NSCLC
1. Genetic susceptibility
A number of genetic polymorphisms that make smokers susceptible to lung cancer
have been identified. For the most part, polymorphisms have been associated with genes
encoding proteins involved in the metabolism, detoxification and gene repair due to
tobacco smoke carcinogens. Polymorphism in CYP1A1, an enzyme that catalyzes the
bioactivation of polyaromatic hydrocarbons (PAH), contributes to tobacco-induced
cancers through their enhanced carcinogen-activating capacity [78]. Polymorphism in
CYP2E1, an enzyme involved in the activation and metabolism of alcohols and
nitrosamines, is also implicated in tobacco-induced carcinogenesis. Using human lung
autopsies, studies correlated higher 7-methyl-dGMP adducts caused by tobacco smoke
with the presence of CYP2E1 minor alleles [72]. CYP2A6 is another enzyme thought to
be responsible for nitrosamine and nicotine metabolism and has been an important target
of research on CYP family gene polymorphisms in relation to lung carcinogenesis. Large
size clinical studies also indicate that deletion-type polymorphism at the CYP2A6 locus
reduces the risk of lung cancer [78].
Similarly polymorphism in genes associated with detoxification of carcinogens are
linked to lung cancer development. Incidence of polymorphisms in glutathione S4

transferase genes (GSTM1, GSTT1, GSTP1 or GSTM3) results in defective enzymatic
activity that lead to increased accumulation of carcinogens. Such accumulation entails
increased rate of PAH DNA adducts as well as higher rate of mutations within specific
genes implicated in the cell cycle and differentiation [79]. Moreover, the risk of lung
cancer

increases

dramatically

in

tumor

samples

that

exhibit

combinational

polymorphisms [199].
Genetic defect in DNA repair genes is another factor that makes smokers susceptible
to lung cancer. Under normal circumstances, DNA repair mechanisms prevent the
accumulation of multiple genetic alterations that could potentially lead to cancer
development. Specifically, studies linked hOGG1 polymorphisms to lung cancer
incidence both in squamous cell lung carcinoma and adenocarcinomas of the lung [211,
218]. hOGG1 is a base excision repair protein that removes a mutagenic base product (8Oxo-2'-deoxyguanosine) that develops from exposure to tobacco smoke, which produces
free radicals in the respiratory tract. If repair is inadequate, DNA damage from these free
radicals results in mutations predisposing smokers to lung cancer [173].
2.

Loss of tumor suppressor genes
Silencing of TSGs is a common event in cancer. TSGs are inactivated in a two-

step process that results in the loss of both gene alleles. Initially, mutations or epigenetic
silencing inactivates one allele followed by loss of a region of the chromosome by
deletion or mitotic recombination through a process called loss of heterozygosity [93].
Common TSGs inactivated in lung cancer include TP53, Rb1, P16 and PTEN.
The p53 pathway: There is a positive correlation between tobacco use and inactivating
mutations in the p53 TSG [77]. The p53 gene is located on chromosome 17p13 and
5

encodes for a 53-kDa phosphoprotein [20]. p53 acts as a transcriptional regulator
implicated in the cell cycle, DNA repair, and apoptosis. During cellular stress, it induces
the expression of the cyclin-dependent kinase (CDK) inhibitor p21cip1, which results in
the G1 cell cycle arrest associated with either DNA repair or apoptosis [36]. p53 was
shown to prevent the accumulation of DNA damage by activating DNA repair genes such
as GADD45. In situations where the damage could not be repaired, p53 promotes the
expression of pro-apoptotic genes such as BAX and Fas [139, 219]. Hemizygous deletion
of the TP53 gene occurs in 65 % of NSCLC, more commonly in squamous cell
carcinoma than adenocarcinomas, and it is associated with male gender, higher tumor
grade and overall unfavorable prognosis in lung cancer [77, 189].
The p16/CDK-cyclin D/Rb pathway: The retinoblastoma (Rb) TSG is located on
chromosome 13q14 and encodes a 110-kDa phosphoprotein. pRb prevents the transition
from G1 to S phase of the cell cycle by sequestering the transcription factor E2F. This
inhibition is however released upon phosphorylation of Rb mediated by complexes of
cyclin D and CDK4/CDK6, which enables cells to enter the S phase in the cell cycle [69,
161]. Although alterations in Rb expression are observed in subsets of NSCLC, the most
striking is the loss of p16 protein upstream of Rb. p16 inhibits the formation of CDKcyclin D complexes, thus leading to decreased phosphorylation of Rb. Hence, loss of p16
results in release of E2F upon Rb phosphorylation and progression into S phase of the
cell cycle [148]. Loss of p16 function in NSCLC cells is attributed to several
mechanisms. NSCLC cells display homozygous or heterozygous deletion within the
coding region of p16. Additionally, hypermethylation of the 5’-CpG island in the
6

promoter region leads to gene silencing [46, 58]. In addition to the loss of Rb and p16
functions, overexpression of cyclin D1 has also been observed in NSCLC [143].
PTEN: Phosphate and tensin homolog (PTEN) is a tumor suppressor gene located on
chromosome

10.

PTEN

removes

the

phosphate

from

the

PI3K

product

phosphatidylinositol (3,4,5)-triphosphate (PIP3) to generate phosphoinositide 4,5biphosphate (PIP2). The decrease in PIP3 attenuates the recruitment of kinases such as
phosphoinositide-dependent kinase-1 (PDK-1), which in turn phosphorylates Akt. Loss
of PTEN expression leads to continuous Akt activity resulting in cell proliferation and
multitude of anti-apoptotic signals [39, 169]. In contrast to other cancers, mutations or
homozygous deletions in the PTEN gene are not common in NSCLC. However,
approximately 70 % of NSCLC have reduced or loss of PTEN expression. These results
suggest that the loss of PTEN expression in NSCLC is regulated at the transcriptional or
translational level [166, 188].
3.

Activation of oncogenes
Unlike inactivation of TSG that involves deletion of both alleles, oncogenes are

activated by mechanisms that target one allele and entail gene amplifications or point
mutations. Several oncogenic dysregulations have been documented in lung cancer
involving KRAS, EGFR, ALK, HER2, MET, PIK3CA, BRAF and ERK (Fig. 1.1). The
following introduction only covers the two most commonly mutated oncogenes in
NSCLC: KRAS and EGFR.
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HER2, 2%
ALK, 5%

MET, 1%

ERK, 1%

PIK3CA,
3%

BRAF, 2%
others or no
mutation
detected, 35%
EGFR, 20%

KRAS, 30%

Figure 1.1 Frequency of mutations and amplifications of major oncogenes in
NSCLC
Approximately 20 % of lung adenocarcinomas harbor EGFR mutations. KRAS mutations
are more frequently found in adenocarcinomas (30 %), which are mutually exclusive with
EGFR mutations. A subset of adenocarcinoma harbors a transforming fusion gene,
EML4–ALK (5 %). The mutation frequency of BRAF is 2 %, PIK3CA 3 %, and
amplifications of MET and HER2 1 % and 2 %, respectively. Nearly 35 % of lung
adenocarcinomas do not harbor currently detectable mutations.

KRAS: Mutations in the KRAS gene have been found in approximately one-third of lung
adenocarcinoma patients. KRAS is a member of the RAS family of small GTPases,
which also includes NRAS and HRAS. The RAS proteins contain a highly conserved Nterminal domain implicated in GTP binding, hydrolysis, and interaction with downstream
effectors. On the other hand, the C-terminus contains domains that are highly variable
and important for post-translational modifications [202]. Activation of RAS begins upon
stimulation of upstream receptors such as receptor tyrosine-kinases (RTKs), which leads
8

to interaction of adapter proteins such as Grb2 with the intracellular domain of RTKs,
and in turn recruits guanine nucleotide exchange factors (GEFs) such as SOS. GEFs
interact with RAS to promote the exchange of GDP to GTP. Once bound to GTP, RAS
proteins activate a large number of downstream effectors implicated in proliferation (e.g.
RAF) and survival (e.g. PI3K) [41, 87].
KRAS is the most commonly mutated RAS protein in lung cancer. KRAS
mutations impair the intrinsic GTPase activity resulting in continuously activated GTP
bound KRAS. Most mutations occur in exon 2 and 3, mainly at codon 12, sometimes at
codon 13, and more rarely at codon 61 [41, 153]. KRAS mutations are mainly seen in
adenocarcinomas of the lung with a history of smoking. The common nucleotide
transversions in lung adenocarcinoma (G to T) are frequent in KRAS mutations and are
associated with smoking [150].
Meta-analysis of various studies indicates that KRAS mutations are negative
prognostic factors for survival of lung cancer patients [132]. It has been reported that
NSCLC patients with wild-type KRAS respond better to chemotherapeutic agents such as
cisplatin and vinorelbine compared to patients with mutant KRAS [52, 174].
Additionally, KRAS mutations, which are mutually exclusive with EGFR mutations, are
associated with lack of response to EGFR tyrosine-kinase inhibitors [180, 213]. Some
studies also reported a lack of significant correlation between KRAS status and diseasefree progression of NSCLC patients. It has been suggested that rather than having a wildtype KRAS or mutant KRAS, specific types of mutations are better predictors in
determining response to therapy and prognosis [174].
9

The Epidermal Growth Factor Receptor (EGFR): Alterations of EGFR are implicated in
the pathogenesis of many tumors, including NSCLC. EGFR encodes an extracellular
ligand-binding domain, a transmembrane domain, and an intracellular region consisting
of a highly conserved tyrosine-kinase domain. Ligand binding induces homodimerization
or heterodimerization of the receptor with other members of the EGFR family, resulting
in autophosphorylation of the tyrosine residues. These phosphorylated tyrosine residues
provide a docking site for SH2 (Src homology) or PTB (phosphotyrosine binding)
domain containing adaptor proteins. EGFR is involved in the regulation of numerous
cellular processes such as cell proliferation, survival, differentiation, invasion and
metastasis. Overexpression of EGFR and its ligand, the transforming growth factor alpha
(TGFα), or activating mutations in EGFR, lead to activation of signaling pathways
including the RAS/RAF/MEK/ERK pathway, the PI3K/Akt/mTOR pathway, and the
stress activated pathway involving JAK and STAT [140].
Overexpression of EGFR or its ligand TGFα occurs in 50-80 % of NSCLC,
specifically in squamous cell carcinomas and its precursor lesions whereas EGFR
activating mutation are more frequent in adenocarcinomas, women, East Asians
background, and people who never smoked. Activating mutations of the EGFR have been
reported in 15-50 % of NSCLC patients (15 % in the case of Caucasian patients and 50 %
of East Asian patients). These mutations are often oncogenic and force the mutated cells
to become addicted on EGFR for survival [95, 187, 213, 215]. Several activating
mutations in the EGFR gene have been described. The two most common are a short-
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frame deletion of exon 19 (delE746-A750) and a point mutation (CTG to CGG) in exon
21 that results in substitution of leucine by arginine at codon 858 (L858R) [94].

EGFR targeted therapies for NSCLC
Monoclonal antibodies to the EGFR and small molecule tyrosine-kinase inhibitors
are in clinical use for lung cancer patients. Monoclonal antibodies including cetuximab,
matuzumab, panitumumab, and necitumumab bind to the extracellular domain of EGFR
and competitively block ligand binding. The antibody-receptor complex formation is
followed by internalization and degradation of the complex, leading to downregulation of
EGFR signaling [57, 85]. The small molecule EGFR TKIs such as gefitinib and erlotinib
compete reversibly with ATP for binding to the intracellular catalytic kinase domain. The
efficiency of these drugs for blocking receptor activity and decreasing cell viability is
significantly higher in cells harboring mutant EGFR (Fig. 1.2) [3].
Preclinical studies have shown that both anti-EGFR antibodies and EGFR-TKIs
block the in vitro growth of human NSCLC cell lines by inhibiting receptor
phosphorylation and downstream protein phosphorylation, including MAPKs and Akt
[3]. Moreover, the two classes of inhibitors have been assessed in combination with
conventional cytotoxic chemotherapeutic drugs or radiation therapy. EGFR monoclonal
antibodies have been shown to synergize with cisplatin or doxorubicin in NSCLC
xenograft models. These antibodies also synergize with radiation and paclitaxel in both in
vitro and in vivo studies. However, in the case of the small molecule inhibitors, neither
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gefitinib nor erlotinib showed improved response rate or disease-free progression when
used in combination with chemotherapeutic agents [24, 85].

Ligand

Ligand
mAB

Cetuximab
Panitumumab
Matuzumab

EGFR

TKI

Erlotinib
Gefitinib
PKI-166
Lapatinib
EKB-569
CI-1033

Figure 1.2 Antibodies and small molecules intercepting EGFR signaling
Anti-EGFR monoclonal antibodies and small molecule EGFR TKIs have been used in
lung cancer treatment. mABs bind to the extracellular domain of EGFR and compete with
endogenous ligands for receptor binding, and block ligand-induced receptor activation.
The small molecule EGFR inhibitors compete with ATP to bind the catalytic domain of
the kinase, which in turn inhibits EGFR autophosphorylation and downstream signaling.
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Resistance to EGFR inhibitors in NSCLC
Despite the initial success of TKIs for the treatment of lung cancer patients harboring
EGFR activating mutations, most patients develop resistance over time and progress to
advanced stages of the disease. Several mechanisms have been reported for this acquired
resistance, including secondary mutations in EGFR, parallel pathway activation,
phenotypic transformation, and additional genetic alterations.
1. Presence of secondary mutations in EGFR
Secondary mutations in EGFR are documented in patients that develop resistance to
EGFR TKIs. The most common is the T790M activating point mutation in exon 20 that
substitutes the gatekeeper methionine for threonine, which interferes with the binding of
reversible TKIs. The T790M substitution changes the affinity of the drug to the ATP
pocket and enables ATP binding at the level of the wild-type EGFR. T790M is found in
about 50 % of patients who developed acquired TKI resistance [94]. The use of secondgeneration TKIs such as afatinib and neratinib, which irreversibly bind to EGFR have
been evaluated to overcome the effect of acquired resistance. Although the results from
preclinical studies have been encouraging, the drugs did not increase response rate and
progression free survival of lung cancer patients [43, 96, 158].
2. Parallel activation of downstream signaling pathways
Resistance to EGFR TKIs could also be acquired through mechanisms that involve
activation of EGFR downstream targets such as Akt and ERK independent of EGFR.
These mechanisms mainly involve amplifications of the MET oncogene and
overexpression of its ligand, hepatocyte growth factor (HGF). These dysregulations
13

bypass inhibition of EGFR and render resistance to TKIs [44, 152]. MET is a tyrosinekinase receptor implicated in cell motility, growth and angiogenesis in various tumors.
Overexpression of HGF or MET amplification has been reported in close to 20 % of lung
tumors exposed to EGFR TKIs. MET receptor activation results in EGFR-independent
phosphorylation of ErbB3 and downstream activation of the PI3K/Akt pathway. This
process allows the survival of cells with MET amplification in the presence of the EGFR
TKI. MET amplification can occur either with or without EGFR T790M mutation.
Although ~ 60 % of MET amplifications occur without the T790M mutation, studies
have also reported a complementary role of the two dysregulations [14].
3. Phenotypic transformation - epithelial to mesenchymal transition
During embryonic development a balance between epithelial to mesenchymal
transition (EMT) and mesenchymal to epithelial transition (MET) maintains proper cell
morphology. Epithelial cells are polarized with tight connection to adjacent cells whereas
mesenchymal cells exhibit a spindle-like morphology. In the context of cancer, EMT is
marked by loss of epithelial cell junction proteins such as E-cadherin and gain of
mesenchymal markers such as vimentin [191]. Mesenchymal type cells also possess
enhanced motility and invasive phenotype, and the expression of genes associated with
EMT has been correlated with poor patient prognosis in NSCLC [21, 209]. Studies have
found that up-regulation of Notch-1 induces mesenchymal phenotype in lung cancer cells
that are resistant to TKIs. Moreover, inhibition of Notch-1 signaling augmented
sensitivity to TKI [210]. The aberrant expression of transforming growth factor (TGF-β)
is also a potent inducer of EMT [160, 212]. Erlotinib-resistant NSCLC cells with
14

mesenchymal phenotype possess high levels of TGF-β expression. In addition, blockade
of TGF-β signaling in combination with EGFR inhibition was shown to have synergistic
effects on EGFR inhibition and cell viability [212].
4. Acquired genetic alterations other than EGFR mutations
PIK3CA mutations - Studies indicate that 5 % of lung cancers that developed acquired
resistance to TKIs have PIK3CA mutations [159]. In several clinical trials, the
combination of a pan-PI3K inhibitor with gefitinib resulted in enhanced efficacy in
patients with acquired resistance to EGFR TKIs. However, many of the patients had
toxicities, underscoring the challenge of blocking the two pathways that are critical for
cell survival [51].
HER2 amplification: Mutations (approximately 2 %) and amplifications (2-5 %) of
HER2, a member of the EGFR family, have been reported in patients with lung
adenocarcinomas. Dysregulation of HER2 in lung cancer is associated with females, nonsmokers, and Asian backgrounds. Additionally, 12 % of lung cancer patients exposed to
TKI have amplification of the HER2 gene and present a more advanced stage of the
disease. HER2 amplification was also shown to be mutually exclusive with EGFR
T790M mutations [115].
ERK2 amplification: Approximately 5 % of tumors resistant to TKIs have amplification
of ERK2. Furthermore, MEK inhibitors effectively restored the sensitivity of EGFR
TKIs. Similar to HER2 amplification, ERK2 amplification is mutually exclusive with
T790M mutation [179].
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BRAF mutation: V600E and G469A, mutations in the BRAF, occur in 1 % of tumor
samples that are resistant to TKIs. Although the V600E mutation appears in patients with
the EGFR T790M mutations, the G469A mutation is mutually exclusive [130].
JAK2: JAK proteins phosphorylate signal transducer and activator of transcription
(STAT), which forms a homodimer that translocates into the nucleus where it binds to
DNA and promotes transcription of genes. Studies have shown that JAK2 activation
induces resistance to EGFR TKIs and that JAK 2 inhibitors restore the sensitivity to
erlotinib in cellular and xenograft models [2, 68].
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1.2 Protein kinase C
Protein kinase C (PKC) belongs to the AGC superfamily of kinases. On the basis
of structural, functional and biochemical properties, PKC have been classified into three
subgroups; conventional, novel and atypical. The conventional (cPKCs α, βI, βII and γ)
are diacylglycerol (DAG) and phorbol ester sensitive and respond to Ca2+. The novel
PKCs (nPKCs δ, ε, η and θ) only respond to phorbol esters or DAG. The atypical PKCs
(aPKCs ι and ζ) are independent of DAG and Ca2+. cPKCs and nPKCs are activated in
response to an increase in DAG levels in the plasma membrane. This increase could be
triggered by activation of receptor tyrosine-kinases, which couple to phospholipase Cγ
(PLCγ), or G-protein-coupled receptors (GPCRs) that couple with phospholipase Cβ
(PLCβ). PLCs in turn hydrolyze phosphoinositide 4,5-biphosphate (PIP2) into second
messengers inositol triphosphate (IP3) and DAG. Binding of DAG (or phorbol esters)
occurs in the C1 domains located in the regulatory region. Additionally, the cPKCs have
a C2 domain that is required for Ca2+ binding. In the case of the atypical PKCs,
regulation is achieved through their N-terminal PB1 domain. Although DAG is an
important lipid second messenger for PKC activation, PKC-mediated responses could
also occur through protein modifications [66].
At the membrane, PKCs undergo conformational changes that release the
inhibition exerted by the pseudosubstrate sequence bound to the active site. In the open
conformation, PKCs undergo a series of serine/threonine phosphorylations to achieve full
activation. Phosphorylation in the activation loop at a TFCGT motif, conserved in many
members of the AGC kinase superfamily, is required for full activation of PKCs. This
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activation is catalyzed by phosphoinositide-dependent kinase 1 (PDK1) recruited by
PIP3. Additional phosphorylations also occur at the C-terminal to lock the kinase domain
in its active conformation [136]. At the plasma membrane, each PKC isozyme interacts
with its anchoring protein, receptor of activated C-Kinase (RACK) and phosphorylates
nearby substrates (Fig. 1.3) [121].
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Figure 1.3 Structure and activation of PKC isozymes
cPKCs contain DAG responsive C1 domains and calcium binding C2 domains. The
nPKC have C1 for the interaction with DAG but lack calcium binding C2 domains.
Atypical PKCs are responsive neither to DAG nor to calcium. Upon increase in DAG
(also calcium for cPKCs), PKCs localize to the plasma membrane where they interact
with their specific anchoring protein, receptor for activated C-kinase (RACK) and
phosphorylate nearby substrates leading to various cellular responses.
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Protein kinase Cs in cancer development and progression
PKC isozymes play important roles in the development and progression of many
cancers by regulating cell cycle, survival, apoptosis, cell motility and malignant
transformation. Although mutations and chromosomal rearrangements of PKC isozymes
are rare events in cancer, altered expressions of PKCs have been associated with the
development of many cancers including lung cancer (Table 1.2). PKCα, PKCβ, PKCδ,
PKCε and PKCι have been implicated in lung cancer malignancy and the following
section focuses on their roles in cancer progression.

Breast

Colon
Lung
Prostate

Alpha
Assender, JW
et al 2007 ↑;
Kerfoot, C et
al 2004 ↓
Suga, K et al
1998 ↓

Beta
GokmenPolar, Y et
al 2010 ↑

Delta

Epsilon
Pan, Q
et al 2005 ↑

Bae, KM
et al 2007 ↑
Metzger, E Kharait, S et Aziz, et al
et al 2010 al 2006 ↑;
2007 ↑; Koren,
↑
Villar et al
R et al , 2004
2007↑
↑; McJilton,
MA et al, 2003
↑

Iota
Kojima, Y et
al. 2008 ↑
Murray, NR et
al. 2004 ↑
Regala, RP et
al. 2005b ↑
Ishiguro, H et
al. 2009 ↑

Table 1.2 Altered expressions of PKC isozymes in primary tumor samples
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PKC α: This PKC plays important roles in many cellular processes such as cell
proliferation, cell cycle, apoptosis, and motility, and regulates the expression of genes
associated with multidrug resistance. PKCα can act as a tumor suppressor or tumor
promoter in different contexts. PKCα has been described as a pro-survival kinase in
breast, endometrial, glioma and androgen-independent prostate cancer cells. These
studies indicate that PKCα mediates mitogenic signals through the activation of the
MAPK pathway, induction of CDK1 and inhibition of p21 [128, 171]. In contrast,
PKCα is widely reported as a tumor suppressor in intestine and skin tumors. Analysis of
tissue samples from PKCα-/- mice indicates higher expression of inhibitor of DNA
binding (Id1) known for its tumorigenic properties in the crypts of the small intestine and
colon tumors [141]. In skin cancer, PKCα overexpression suppresses tumor formation
induced by the carcinogen DMBA. Similarly, PKCα has been shown to act as a tumor
suppressor in KRAS-driven lung cancer models [73], and activation of PKCα in H358,
H441 and H322 NSCLC cells in late G1/early S phase leads to senescence through upregulation of p21cip1 [133]. In contrast, a PKCα antisense oligonucleotide (ODN)
exhibited additive antitumor effects on lung carcinomas, and depletion of PKCα in
human lung carcinoma LTEP cells, significantly reduced tumor formation and size in
nude mice underscoring the divergent role of PKCα in lung cancer cells [196].
PKCα is ubiquitously expressed in human tissues, but exhibits altered expression
in various cancer tissue samples [90]. A study on the role of PKCα in bladder cancer
reported that tumor specimens have elevated levels of PKCα compared to normal bladder
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tissue. Moreover, the levels of PKCα correlate with the malignant grade of the tumor
samples [4]. There are controversial reports regarding the relationship between PKCα
expression and advanced stages of breast cancer. Several clinical studies correlated
overexpression of PKCα with advanced breast carcinoma and poor clinical outcomes of
endocrine therapy. Tumor samples that have high staining for PKCα are negative for
estrogen receptor expression. On the other hand, a clinical study involving 46 advanced
stage breast cancer patients showed low PKCα staining in tumors compared to normal
tissue [90]. In endometrial tumors, PKCα staining was variable among patients and
different sections of tumors. Nevertheless, overall endometrial tumors express high
PKCα levels relative to normal tissue [70]. Analysis of 30 tissue samples derived from
human colorectal cancer patients indicated low expression of PKCα in tumor specimens
[172]. Likewise, malignant renal cell carcinoma (RCC) tumors have much lower PKCα
staining than benign oncocytomas [194] .
By far the most consistent function of PKCα is its role in cell motility in different
cancer types. PKCα has been implicated in migration of NSCLC cells in response to
cytokines [31]. ErbB2-dependent activation of PKCα promotes cell invasion in breast
cancer cells [183]. In glioma, the phorbol ester PMA enhances invasion and migration
through activation of PKCα [105]. Activation of PKCα in response to various stimuli
also induces invasion and migration in hepatocellular, melanoma, ovarian and
endometrial cancer cells [22, 112, 197, 208].
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PKCβ : PKCβI and PKCβII are the two splice variant of PKCβ derived from the same
gene. PKCβ is mainly implicated in inflammation and angiogenesis but also plays roles
in cell cycle, proliferation, differentiation and metastasis. The role of PKCβ is well
reported in prostate, breast and colorectal cancers, as well as in lymphomas and
glioblastomas.
PKCβI is highly expressed in prostate cancer tumors compared to benign prostatic
hyperplasias [116]. In the case of PKCβII, high levels are localized in endothelial cells
leading to increased angiogenic capacity of prostate cancer cells. Furthermore, PKCβII
controls cell proliferation and tumor growth. In vivo, tumor formation of PC3 cells was
attenuated using a PKCβII specific inhibitor [64]. PKCβII protects chronic lymphocytic
leukemia cells from apoptosis by regulating Bcl2 and Bim proteins. Phosphorylation of
Bcl2 by PKCβ leads to inhibition of apoptosis by sequestering Bim. Moreover, high
stromal PKCβII was found in patients with various hematological malignancies, which
correlates with more aggressive stages of the disease. PKCβ is shown to regulate the
activation of stromal NF-κΒ that results in the survival of leukemic B cells. In vivo,
crossing T cell leukemia (TCL) transgenic mice that develop leukemia with PKCβ
deficient mice abrogated the development of chronic lymphocytic leukemia (CLL) [111].
In colon and breast carcinomas, the two splice variants have opposite roles.
PKCβII enhances proliferation of intestinal epithelium and is required for the initiation of
colon cancer [168]. Transgenic mice that overexpress PKCβII develop preneoplastic
lesions and become susceptible to azoxymethane-induced colon carcinogenesis. The
levels of colonic β-catenin were also elevated, accounting for proliferation due to
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activation of the PKCβ/Wnt/APC/β-catenin pathway [125]. Furthermore, PKCβII
promotes cell invasion through mechanisms that involve the RAS/MAPK and Rac1
pathways. Spindler et al. reported that 18 % of primary colon adenocarcinomas exhibit
very high levels of PKCβΙΙ, and high expression of PKCβII correlates with poor survival
rates [168]. On the contrary, overexpression of PKCβΙ suppresses tumor formation of
HT29 and SW480 colon cancer cells in xenograft models [61]. In breast cancer,
overexpression of PKCβI suppresses proliferation, tumorigenic capacity, and metastasis
while high levels of PKCβII are reported in several breast cancer cell lines and patient
samples [101]. In murine cell lines derived from mammary tumors, overexpression of
PKCβI leads to increased latency and slow growth of tumors in mice. Moreover, tumor
cells that overexpress PKCβI have attenuated metastatic capacity to the lungs. On the
other hand, PKCβII regulates VEGF-induced angiogenesis and growth in breast cancer
cells. The expression levels of cytoplasmic PKCβII positively correlate with HER2 levels
while nuclear PKCβII correlates positively with ER levels [60].
PKCβ reduces apoptotic signals and cell invasion in gastric and hepatocellular
carcinomas. In hepatocellular carcinomas, PKCβII-mediated ERK/heat shock protein 27
(HSP 27) activation is responsible for cell motility and invasion. Down-regulation of
PKCβI expression and activity by a COX-2 specific inhibitor (SC-236) attenuates
apoptotic response of gastric cancer cells [216]. Much of the studies on glioblastomas and
lung cancer cells were done with the PKCβ specific inhibitor enzastaurin. In
glioblastomas, PKCβ regulates proliferation by suppressing the activity of GSK3, S6
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kinase and Akt. Moreover, the effect of the PKCβ inhibitor was shown using U87MG
human glioblastoma cells inoculated in nude mice [185]. In NSCLC, treatment with
enzastaurin inhibits the transcription of genes associated with tumor progression such as
u-PAR and VEGF-C and up-regulates tumor suppressors. PKCβ inhibition in NSCLC
cells also resulted in reduced migration, invasion and metastasis [204].
PKCδ: PKCδ functions as a tumor suppressor as well as a pro-survival kinase in several
cancer cell types. PKCδ activation depends on multiple factors such as proteolytic
activation, tyrosine phosphorylation, intracellular localization, and the nature of apoptotic
stimuli [11]. Studies have shown that activation of PKCδ inhibits cell cycle progression
and down-regulation of PKCδ facilitates tumor formation. In lung cancer cells,
overexpression of PKCδ led to PMA induced G1 arrest by regulating the expression of
cell cycle inhibitor p21cipl [127, 156]. Suppression of p53 due to an increase in PKCδ
expression was associated with colon cancer progression. The function of PKCδ as a proapoptotic protein was further established by the observation that treatment with genotoxic
agents results in cleavage of PKCδ by caspase-3 [149]. In androgen-dependent prostate
cancer cells, PKCδ activation by PMA triggers the extrinsic apoptotic cascade through
the activation of an autocrine loop that involves the secretion of the apoptotic factors
TNFα and TRAIL. This pro-apoptotic cascade can be blocked with pharmacological
agents against p38 MAPK and JNK, suggesting a role for MAPK cascade as effectors of
the apoptotic response mediated by PKCδ [63]. Contrary to its role as a pro-apoptotic
kinase, studies in breast, lung, pancreatic and liver tumor models have linked PKCδ to
survival and enhanced resistance to anti-cancer drugs [11]. PKCδ specific inhibitors as
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well as kinase-dead mutants were shown to attenuate cell survival in NSCLC and breast
cancer cells. Moreover, PKCδ expression was found to be higher in estrogen receptorpositive human breast tumors. Ectopic expression of PKCδ also enhanced anchorageindependent growth and resistance to cytotoxic drugs in pancreatic and liver cancer cells
[120]. Studies using genetically engineered mouse models also contribute to unravel roles
of PKCδ in tumorigenesis. For example, PKCδ skin transgenic mice are resistant to
tumor promotion by DMBA and PMA [145]. In lung cancer, KRAS-driven lung
tumorigenesis was abrogated in PKCδ knockout mice [176]. Similarly, ErbB2
overexpressing mice in a PKCδ−null background delays breast tumorigenesis [1].
PKCδ is generally reported as a positive regulator of cell motility. In pancreatic
and renal cell carcinoma, PKCδ phosphorylation led to enhanced cell motility [45, 120].
In glioma cells, PKCδ increased MMP-12 expression, which results in increased invasion
[157]. Overexpression of claudin-1 activates a c-Abl-PKCδ signaling pathway, leading to
a marked elevation in MMP-2 activity and invasion in human liver cancer cells [214].
The chemokine CCL5 induces the production of MMP-9 and an invasive phenotype in
oral cancer cells also via a PKCδ-dependent mechanism [34]. In prostate cancer cells,
PKCδ activation induces migration downstream of EGFR. Moreover, overexpression of
PKCδ in prostate cancer cells enhances collagen secretion [193]. In gastric carcinoma
cells, TGF-β-induced PKCδ expression enhances cell spreading, motility and invasion
[32].
PKCε: This nPKC is overexpressed in many cancer types including skin, breast, lung,
prostate, renal and head and neck squamous cell carcinoma. Overexpression of PKCε in
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these cancers is associated with the development and progression of the disease. High
PKCε staining in primary breast tumors correlates with a high histological grade, positive
HER2 receptor status, and loss of hormone receptor [12]. Overexpression of PKCε has
also been reported in greater than 90 % of NSCLC and prostate tumors [7].
PKCε functions as an anti-apoptotic kinase through its regulation of the cell cycle
and expression of genes associated with cell survival. Studies have shown that
PKCε promotes cyclin D1 induction leading to G1 to S phase progression during the cell
cycle. Moreover, PKCε has been implicated in mitogenic signals through mechanisms
that involve caspases, Bcl2 family members, the Raf/MEK/ERK pathway and other prosurvival molecules [25, 26]. In NSCLC, PKCε protects cells against TRAIL-induced
apoptosis and depletion of PKCε leads to enhanced expression of pro-apoptotic proteins.
PKCε inhibition also attenuates tumor growth and metastatic dissemination in nude mice
[25, 47]. In prostate cancer, PKCε depletion impairs the activation of the NF-κΒ pathway
in response to TNFα. Moreover, overexpression of PKCε in normal immortalized
prostate epithelial cells causes ERK and Akt activation and confers growth advantage.
Prostate-specific overexpression of PKCε in mice led to the formation of preneoplastic
lesions [18, 54]. Additionally, in androgen-dependent LNCaP cells, overexpression of
PKCε results in tumor growth in nude mice. Similarly, overexpression of PKCε enhances
tumorigenic and metastatic potential of breast cancer cells [108]. The role of PKCε in
skin cancer initiation and progression has been shown using a skin-specific PKCε
overexpressing transgenic mouse model. These mice exhibit phenotypic abnormalities
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including inflammation, hyperkeratosis and ulceration resulting in a highly malignant and
metastatic squamous skin cell carcinoma [203].
PKCι: This aPKC is an oncogene required for maintenance of the transformed phenotype
of NSCLC cells with KRAS mutations. Moreover, the PKCι-Par6-Rac1 signaling was
found to be important for the transformation of NSCLC cells [50, 146]. PKCι also
regulates the Rac1/Pak1/MEK/ERK signaling pathway involved in cell proliferation of
NSCLC cells [147, 217]. Gene expression microarray analysis of U87MG glioma cells
showed that PKCι suppressed the expression of RhoB, which has previously been
reported to have a role in actin stress fiber formation [8]. In vitro and in vivo experiments
also revealed the involvement of PKCι in prostate cancer cell growth through secretion of
IL-6. Indeed, PKCι activates transcription of the IL-6 gene through NF-κΒ and AP-1,
thus arguing for its involvement in hormone-independent prostate cancer cells [82]. PKCι
is also a potential oncogene in ovarian cancer, as enhanced PKCι protein levels are
associated with increased cyclin E protein expression and proliferation in ovarian cancers
[217].
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1.3 Nuclear factor-κΒ (NF-κΒ) transcription factors
Nuclear factor-κB (NF-κΒ) represents a family of structurally related
transcription factors that are implicated in various cellular processes including
inflammation, proliferation, angiogenesis, transformation, apoptosis, invasion, and
resistance to chemotherapy and radiation therapies. There are five members of the
mammalian NF-κΒ family; RelA (p65), RelB, c-Rel, NF-κΒ1 (p50/p105) and NF-κΒ2
(p52/p100). Each member contains a highly conserved 300 amino acid N-terminal region
called Rel homology domain (RHD). This region comprises sub-domains for
dimerization, nuclear localization (nuclear localization sequence, NLS) and DNA
binding. The five members are further subdivided into two groups based on their catalytic
activity. RelA, RelB and c-Rel contain C-terminal transactivation domains, which are
made up of serine and hydrophobic amino acids important for the transactivational
activity. The RHD of RelA and c-Rel contains a phosphorylation site for Protein Kinase
A (PKA) that is important for transcriptional activity. In the case of the NF-κΒ proteins
p100 and p105, the C-terminal region consists of multiple copies of ankyrin repeats,
which keeps the proteins in their inactive form. The NF-κΒ proteins are converted to
active DNA-binding proteins (p105 to p50, and p100 to p52) by proteolytic cleavage or
arrested translation, and as they lack the transactivation domain, they cannot act as
activators of transcription except when they form dimers with the Rel proteins. NF-κΒ
family members form multiple homo-and heterodimers depending on the cell type, nature
of the stimulus, and the length of exposure. In general, p50/RelA or p52/RelA complexes
are the most common dimers [13, 59].
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NF-κΒ activation pathways
Activation of NF-κΒ occurs primarily by two signaling pathways; canonical and
non-canonical pathways. Activation of the IκΒ kinase (IKK) complex is the common
upstream regulatory step in both pathways of NF-κΒ activation. The IKK complex
includes catalytic kinase subunits IKKα and IKKβ, and a regulatory subunit called NFκΒ essential modulator (NEMO). Although the signals mediated by IKKα and IKKβ
differ, both could phosphorylate IκΒ and exhibit similar structural organization, including
kinase domain, leucine zipper and helix-loop-helix domains with 52 % amino acid
homology. IKKs become activated via phosphorylation of serine residues in the kinase
domain (residues 176 and 180 in the case of IKKα and residues 177 and 181 in the case
of IKKβ) by IKK kinases. The canonical pathway is activated in response to multiple
stimuli, such as ligand binding to TNF receptors, IL-1 receptors, T-cell receptors, B-cell
receptors, and Toll-like receptor 4 (TLR4). This pathway induces the transcription of
genes implicated in inflammatory response, cell motility and growth [29, 59, 80].
Association of NF-κΒ dimers with their inhibitory proteins, inhibitors of NF-κΒ
(IκB), sequesters the complex in the cytoplasm during the inactive state. The human IκΒ
family of inhibitory proteins includes IκΒα, IκΒβ, IκΒγ, and IκΒε, which have different
affinities for individual NF-κΒ dimers. IκΒs possess several ankyrin repeats, which are
33 amino acid sequences that mediate binding to NF-kB dimers. Unprocessed NF-κΒ1
(p105) and NF-κΒ2 (p100) also function as IκΒ proteins. IκΒ proteins sequester the NFκΒ dimers in the cytoplasm by hiding their nuclear localization sequences. With the
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exception of IκΒβ, the expression of IκΒ proteins is regulated by NF-κΒ resulting in an
autoregulatory loop of NF-κΒ signaling. The NF-κΒ/IκΒα complex is activated by
phosphorylation on conserved serine residues in the N-terminal portion of IκΒ. This
modification occurs at ser-32 and ser-36. Phosphorylation targets IκΒα for ubiquitination
by the SCF-ubiquitin ligase complex, which leads to the degradation of the inhibitory
subunit by the 26S proteasome. This process enables the p50/p65 dimer to translocate to
the nucleus and bind to its DNA-binding site in the promoter or enhancer regions of
specific genes. Several modifications of the p65 protein occur during active transcription
of target genes. Phosphorylation of the p65 subunit by PKA or MAPKs at ser-276 is
important for the recruitment of cAMP response element-binding (CREB) protein/p300
[59]. Additionally, phosphorylation by casein kinase II and IKKs increases the
transcriptional activity of NF-κΒ. Epigenetic modifications such as acetylation,
methylation and demethylation of p65 also play a key role in the regulation of NF-κΒ
transcriptional activity [28].
In the case of the non-canonical pathway, activation of NF-κΒ is triggered by
ligand binding to lymphotoxin β receptor, B-cell-activating factor, CD40, and CD30.
Activation of the non-canonical pathway is involved in the development of lymphoid
organs and the adaptive immune system. This pathway depends on the recruitment of
TNF associated factor (TRAF) to the membrane and activation of IKKα by NF-κΒ
inducing kinase (NIK). Activated IKKα forms a homodimer and phosphorylates p100,
leading to its ubiquitination and generation of the p52 protein. p52 forms a heterodimer
with RelB and localizes to the nucleus [59]. A third pathway that does not involve IKKs
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has also been described for NF-κΒ activation. This atypical pathway includes DNA
damage followed by activation of casein kinase 2 downstream of p38, resulting in
phosphorylation and degradation of IκΒ (Figure 1.4) [175].
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Figure 1.4 NF-κΒ activation pathways
In the canonical pathway, TNFα, IL-1β or LPS binds to their respective receptors and
lead to IKK-mediated activation of IκΒα. IκΒα is degraded following activation and
release p50/p65 to localize to the nucleus. In the non-canonical pathway, lymphotoxin β
(LTβ) or B-cell activating factor (BAFF) are implicated in NF-κΒ inducing kinase
(NIK)-mediated activation of IKKα. IKKα then phosphorylates p100, which then
undergoes proteasomal processing to generate p52. RelB/p52 dimers are then released
and translocate to the nucleus. The atypical pathway is triggered by DNA damage, which
activates p38-induced casein kinase-2 (CK-2) and results in phosphorylation of IκΒα.
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NF-κΒ and cancer
Dysregulation of the NF-κΒ signaling pathway is a common feature of many
human diseases including cancer. NF-κΒ is important in integrating multiple stress
stimuli and regulating innate and adaptive immune responses seen in inflammation,
which is associated with or precede cancer initiation [15]. NF-κΒ activation occurs in
premalignant cells that are destined to undergo malignant conversion as well as in cells
that are recruited to the tumor microenvironment. These cells produce cytokines,
angiogenic factors, and proteases that degrade the extracellular matrix to support cancer
development and progression. The microenvironment cells include macrophages,
dendritic cells, neutrophils, mast cells, T cells and B cells [13]. Generation of several
inflammatory cytokines, including TNFα, IL-1β and IL-6, in some of these cells is
known to be dependent on the canonical NF-κΒ pathway activation induced by
inflammation. Secreted TNFα and IL-1β act on the premalignant cells to activate NF-κΒ,
which induces expression of genes involved in inhibition of apoptosis and promotion of
proliferation and angiogenesis. NF-κΒ activation in the microenvironment cells could
also promote production of reactive oxygen species (ROS), which induce DNA damage
of the premalignant cells. Such DNA damage activates NF-κΒ, which induces expression
of anti-apoptotic genes to promote cancer progression [29, 59].
Various studies identified the role of NF-κΒ in both hematological and solid
tumors. A viral homolog of c-Rel was shown to cause aggressive lymphomas and
leukemias in chickens [27]. A wide variety of haematopoietic proliferations show
dysregulated NF-κΒ signaling pathway including mutations in IκΒα, amplification of c32

Rel, and chromosomal rearrangements in the NF-κΒ2 gene. In solid tumors, mutations of
the NF-κΒ signaling pathway have been documented in breast and prostate cancers [178].
Studies have shown mutations in the NF-κΒ1, IKKβ as well as IκΒα and IκΒε as well as
high levels of c-Rel in breast cancer [144]. A transgenic mouse that overexpressed c-Rel
in the mammary gland developed one or more mammary tumors and had increased
expression of NF-κΒ target genes, such as cyclin D1, c-myc and Bcl-XL [17]. In prostate
cancer, gene fusion between IKKβ and transpoortin 1 resulted in elevated IKKβ
expression [138]. Although RelA, RelB and NF-κΒ1 mutations are rare in other human
cancers, these subunits are constitutively activated in a wide variety of human tumors.
Increased RelA nuclear localization or activity is present in many tumors and is
associated with tumor progression [74]. Gastric carcinoma shows increased nuclear
translocation of RelA in comparison with adjacent normal epithelial cells and correlates
with tumor invasion. NF-κΒ activation has also been identified in squamous cell
carcinomas of the head and neck. Inhibition of NF-κΒ activity in these tumors attenuates
cell survival and tumor growth[190]. The expression of IKKα has been correlated with
increased expression of NF-κΒ and COX-2 in colorectal carcinomas. In vitro studies
have also suggested a positive role for NF-κΒ in cell transformation in prostate and colon
epithelial cells, fibroblasts, and lymphocytes [55, 195]. In lung cancer, tumor samples
showed high levels of NF-κΒ activation associated with advanced stage of disease and
poor prognosis. NF-κΒ activation in lung cancer has also been correlated with loss of p53
function and KRAS mutation and mediates secretion of inflammatory cytokines that play
an important role in lung cancer development [118].
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PKC and NF-κΒ in cancer
The PKC family has long been known to play an important role in cell growth and
differentiation by regulating the activity of transcriptions factors such as NF-κΒ. Phorbol
esters can induce transient activation of NF-κΒ and control the expression of MMPs [75].
It has also been shown S6 kinase is responsible for phosphorylation of IκΒα at Ser-32
after PMA stimulation [135]. Initial studies that link PKCs to NF-κΒ activation in cancer
were reported for atypical PKCs. PKCζ phosphorylates and inactivates NF-κΒ upstream
kinase, IKKβ at ser-177 and ser-181 in response to TNFα. Additionally the loss of PKCζ
was shown to impair RelA phosphorylation and inhibit the translocation of NF-κΒ to the
nucleus. Deletion of PKCζ reduces NF-κΒ activation in lung in response to both TNFα
and IL-1β [40, 124]. The other atypical PKC isozyme, PKCι also mediates
phosphorylation of IKKβ in response to TNFα and induces NF-κΒ dependent
transcription of the IL-6 in prostate cancer. Recently, our laboratory identified a key role
of PKCε in TNFα dependent activation of NF-κΒ in prostate cancer. PKCε was shown to
be a part of the TNFRI signaling complex that leads to NF-κΒ activation [54]. Yet
another novel PKC isozyme, PKCδ was reported to facilitate RelA binding to the
promoters of target genes in the nucleus [110]. Inhibition of both PKCδ and PKCε has
been shown to prevent TNF-α-induced NF-κΒ activation, determined by NF-κΒ binding
activity and IκΒα degradation in pancreatic cancer cells. Activation of the NF-κΒ
pathway is also attributed, in part, to alterations in classical PKCs. PKCβ dependent
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activation of NF-κΒ, through modulation of the IKK complex, was found to be crucial in
the survival of chronic lymphocytic leukemia [111, 123]. For PKCα, the mechanism for
it interactions with NF-κΒ was first shown using in vitro binding assays. PKCα forms a
complex with NF-κΒ upstream kinase, IKK. Additionally PKCα have been shown to
interact with IKKβ in response to PMA in 293T cells [135]. Mechanism for PKCα
dependent NF-κΒ activation was also extended to phosphorylation of RelA in glioma
cells. In these cells, PKCα mediated activation of NF-κΒ results in pro-survival
phenotype [126].
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Overall goals and significance of research
The goal of my thesis research has been to identify the association between PKC
isozymes and different processes that contribute to lung cancer malignancy. Specifically,
I focused on three different aspects: drug resistance, inflammation and tumorigenesis.
First, I aimed to determine whether PKCs modulate erlotinib resistance in
NSCLC. I used parental and derived erlotinib-resistant cell lines to profile PKC isozyme
expression and study their roles in altering drug sensitivity and mesenchymal phenotype.
The outcome of my study established PKCα and PKCδ as important regulator of erlotinib
sensitivity. Moreover, high expression of PKCα was found to be important for the
maintenance of the mesenchymal phenotype. Second, I wished to identify the
requirement of PKCs for interleukin mediated NF-κΒ activation. I was able to show that
activation of NF-κΒ in response to IL-1β is dependent on PKCα. These studies will
contribute to establish PKCα specific inhibitors as combinational therapeutic options
with indications of TKI resistance and NF-κΒ hyperactivation.
Finally, based on previous findings from our lab implicating PKCε signaling to
lung cancer progression, I aimed to identify whether its function also extends to
tumorigenesis using animal models. I crossbred KRAS mutant mice with PKCε knockout
mice, to study if PKCε modulates oncogenic driven tumor formation. In addition, I aimed
to generate an inducible PKCε transgenic mouse model that could be used to study
whether PKCε could by itself drive lung tumor formation.
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Abstract
Overexpression and mutational activation of the epidermal growth factor receptor
(EGFR) plays an important role in the pathogenesis of non-small-cell lung cancer
(NSCLC). EGFR tyrosine kinase inhibitors (TKIs) are given as a primary therapy for
patients with EGFR activating mutations; however, the majority of these patients
eventually develop resistance to TKIs. To address a potential role of PKC isozymes in the
resistance to TKIs we used an isogenic model: the NSCLC H1650 cell line and its
erlotinib-resistance derivative H1650-M3. H1650-M3 cells display a mesenchymal-like
morphology driven by TGFβ signaling [212]. We found that H1650-M3 cells display
remarkably high levels of PKCα and reduced levels of PKCδ. Notably, RNAi depletion
of PKCα from H1650-M3 cells caused a significant reduction in the expression of EMT
markers vimentin, Zeb2, Snail and Twist. Moreover, pharmacological inhibition or
silencing of PKCα sensitized H1650-M3 cells to erlotinib. Whereas ectopic
overexpression of PKCα in parental H1650 cells did not alter the expression of EMT
genes or confers resistance to erlotinib, it resulted in down-regulation of PKCδ
expression. Forced PKCδ overexpression in H1650-M3 cells also sensitizes the resistant
cells to erlotinib. In addition, we observed that treatment of H1650-M3 cells with the
TGF-β inhibitor LY2109761 attenuates the expression of PKCα. Moreover, PKCα
overexpression cooperates with TGF-β for the induction of specific EMT markers. Our
results highlight a potential role for PKCs in EMT and erlotinib resistance in lung cancer
cells, and suggest a potential therapeutic role for PKCα inhibition in lung cancer
treatment.
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2.1 Introduction
Lung cancer remains one of the major causes of mortality worldwide, accounting
for more deaths than any other cancer cause. Diagnosis of lung cancer normally occurs in
late stages of the disease process, thus limiting the options for treatment. The most
common type of lung cancer (~85 %) is non-small cell lung cancer (NSCLC), which
includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [24, 162].
Genetic alterations in NSCLC tumors have been extensively studied, and include
primarily oncogenic mutations in epidermal growth factor receptor (EGFR) and KRAS,
as well as inactivation of tumor suppressor genes such as p53, PTEN, Rb, and p16 [77,
86, 148]. Mutations in EGFR, particularly deletion of exon 19 and L858R mutation in
exon 21 occur in 10-50% NSCLC patients depending on the population studied [36, 56].
Small molecule tyrosine kinase inhibitors (TKIs) that reversibly inhibit EGFR at the ATP
pocket domain, such as erlotinib and gefitinib, currently represent the first-line
therapeutic option for EGFR-mutated NSCLC patients [3]. Although these therapies are
initially efficacious, ultimately most patients develop resistance. Whereas resistance has
been attributed in some cases to the acquisition of mutations in EGFR (such as the
T790M mutation) or MET amplification [44, 94], the mechanisms behind the resistance
to TKIs have not been fully evaluated. A deep understanding of the signaling
mechanisms driving resistance is crucial for designing combinational therapy regimes to
overcome this hurdle and extend life expectancy of NSCLC patients.
Protein kinase C (PKC) represents group of serine-threonine kinases involved in a
variety of cellular functions, including mitogenesis, survival, and motility. This family of
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kinases is composed of 11 members classified into three classes based on their
biochemical and structural properties: calcium-dependent or conventional PKCs (cPKCα,
βI, βII, and γ), calcium-independent or novel PKCs (nPKCδ, ε, η, and θ), and phorbol
ester/diacylgycerol (DAG) unresponsive or atypical PKCs (aPKCsζ and ι/λ) [66].
Decades of research have established key roles for different members of the PKC family
in the progression of cancer [53, 66]. Individual PKC isozymes can either act as tumor
promoters or tumor suppressors in various cancers including lung cancer. For example,
PKCβ has been proposed to be involved in lung tumorigenesis, and the PKCβ inhibitor
enzastaurin has been studied as a potential anti-cancer agent for lung cancer patients
[186, 204]. Our laboratory recently showed that PKCε, a kinase implicated in cell cycle
progression and motility of NSCLC cells, is required for the tumorigenic and metastatic
activities of NSCLC cells [25, 26]. On the other hand, PKCα and PKCδ negatively
modulate NSCLC cell cycle progression. Most recently, Hill et al. provided direct
evidence for a tumor suppressive role of PKCα in KRAS driven tumorigenesis [73].
Other reports on the contrary indicate that PKCα promotes NSCLC cell migration [31]
arguing for divergent roles for this kinase in lung cancer progression. Likewise, diverse
roles for PKCα and other members of the PKC family have been established in cell
survival in NSCLC and other cancer types.
Towards the goal of determining a potential role of PKC isozymes in TKI
resistance in lung cancer, here we took advantage of an isogenic NSCLC cell model of
erlotinib-resistance generated by culturing the parental H1650 cell line in the presence of
a high concentration of the TKI. Erlotinib-resistant cells were shown to display features
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of epithelial-to-mesenchymal transition (EMT), a phenotype that was found to be
maintained by the transforming growth factor beta (TGF-β) pathway [212]. Our study
identified discrete roles for PKC isozymes in erlotinib resistance and EMT in NSCLC
cells.
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2.2 Results
Erlotinib-resistant cells display altered expression of PKC isozymes
Changes in the expression levels of PKC isozymes have been associated with the
progression of many types of cancers, including lung cancer [53]. In order to determine a
potential involvement of PKC isozymes in erlotinib resistance, we took advantage of an
isogenic NSCLC cell model; the parental H1650 cell line and its erlotinib-resistant
derivative H1650-M3 [212]. H1650 cells express the conventional PKCα, novel PKCδ
and PKCε, and atypical PKCs. Western blot analysis shown in Fig. 2.1A revealed a
remarkable up-regulation of PKCα in the erlotinib-resistant variant H1650-M3. H1650M3 cells also have reduced PKCδ levels. Determination of mRNA levels for these two
PKCs led to similar conclusions. Indeed, H1650-M3 cells have 25-fold higher PKCα
mRNA levels than the parental H1650 cells, whereas PKCδ mRNA levels are reduced by
5-fold in the erlotinib-resistant cell line (Fig. 2.1B).

PKCα is required but not sufficient to induce erlotinib resistance
To assess a potential association between altered PKCα expression and erlotinibresistance, we used both pharmacological and RNAi approaches. As PKCα has been
implicated in drug resistance in some cancer types [30, 99, 220] and its levels are
strikingly high in erlotinib-resistant cells, we speculated that this PKC is involved in
acquired resistance to erlotinib in NSCLC cells.
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Figure 2.1. Erlotinib-resistant cells are characterized by altered expressions of PKC
isozymes
(A) Expression of PKC Isozymes was analyzed in parental (H1650) and erlotinibresistant (H1650-M3) cells. Protein levels of PKCs were determined by Western blot. (B)
mRNA levels of PKCα and PKCδ were measured using real-time quantitative PCR in
H1650 and H1650-M3 cells. Human 18S rRNA was used as an endogenous control.
Fold-changes in mRNA levels were determined by normalizing to mRNA levels in
H1650 using the ΔCt method. **, p < 0.01; ***, p < 0.001
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In initial experiments (Fig. 2.2A), we observed that treatment of H1650-M3 cells with the
pan PKC inhibitor GF 1090203X (5 µM, added 1 h before and during erlotinib treatment)
increases the sensitivity of H1650-M3 cells to erlotinib (10 µM). Next, we examined the
action of Gö6976, which preferentially inhibits cPKCs. As shown in Fig. 2.2B, Gö6976
(5µM) also enhances the killing effect of erlotinib in H1650-M3 cells. As PKCα is the
only cPKC expressed in these NSCLC cells, these results suggest the possibility that
PKCα mediates erlotinib resistance.
To unambiguously establish a role for PKCα in erlotinib resistance, we used
RNAi. Two different PKCα RNAi duplexes, were transfected into H1650-M3 cells,
which deplete PKCα by > 90 % upon delivery into H1650-M3 cells relative to a nontarget control RNAi duplex (Fig. 2.2C, inset). A dose-response analysis for inhibition of
cell viability by erlotinib treatment established an IC50 = 5.1 ± 0.8 µM (n=3) in control
H1650 cells (which is similar to parental H1650 cells, [212] and data not shown). On the
other hand, IC50 in H1650-M3 cells was > 20 µM (n=3), as determined in a previous
study [212]. Notably, PKCα depletion sensitizes H1650-M3 cells to erlotinib, as
determined by the reduction in IC50 (8.7 ± 1.4 µM, for PKCα #1 RNAi; 9.2 ± 3.0 µM, for
PKCα #2 RNAi) (Fig. 2C). To determine if PKCα up-regulation plays a role in inducing
erlotinib resistance, we overexpressed PKCα in parental H1650 cells using an adenovirus
(Adv). A LacZ Adv was used as control (Fig. 2.2D, inset). We found that PKCα
overexpression failed to alter the response of H1650 cells to erlotinib (IC50 = 4.7.± 1.3
µM, for PKCα AdV; IC50 = 5.5 ± 2.0 µM, for LacZ Adv). Thus, our data indicate that
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although PKCα is required for the resistance of NSCLC cells to erlotinib, overexpression
of this kinase is not alone sufficient to induce erlotinib resistance.
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Figure 2.2 PKCα protects H1650-M3 cells from erlotinib induced cell death
(A) Erlotinib-resistant (H1650-M3) cells were pre-treated for 1 h with vehicle or the panPKC inhibitor GF109203X (5 µM). Cells were then treated with erlotinib (10 µM), and
cell viability was determined 24 h later using MTS. **, p<0.01. (B) Erlotinib-resistant
(H1650-M3) cells were pre-treated for 1 h with vehicle or a classical PKC inhibitor
Gö6976 (5 µM). Cells were then treated with erlotinib (10 µM), and cell viability was
determined 24 h later using MTS. *** p<0.001. (C) Parental H1650 and erlotinibresistant (H1650-M3) cells were seeded in 96-well plates. H1650-M3 cells were
transfected with either PKCα RNAi duplexes (α1 or α2) or non-target control (NTC).
After 48 h, cells were treated with erlotinib at the indicated concentrations. Cell viability
was determined 24 h later using MTS. (D) H1650 cells were infected with either LacZ
Adv or PKCα Adv (30 MOI). 5 days following infection, H1650-PKCα were seeded in
96-well plates and treated with erlotinib at the indicated concentrations the following day.
Cell viability was determined 24 h later using MTS.
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PKCδ alters the sensitivity of H1650-M3 cells to erlotinib
Our results clearly ascribe a role for PKCα in determining the sensitivity of
H1650 cells to erlotinib. The fact that H1650-M3 cells display PKCδ down-regulation
relative to parental cells prompted us to investigate whether changes in PKCδ levels
could also dictate the sensitivity to the TKI. It has been reported that PKCδ mediates
cytotoxic effect of several anti-cancer drugs [81, 221]. To address this issue, we
overexpressed PKCδ in H1650-M3 cells using a PKCδ Adv. A LacZ Adv was used as a
control (Fig. 2.3A). As shown in Fig. 2.3B, overexpression of PKCδ in erlotinib-resistant
cells caused a reduction in the IC50 for erlotinib. The effect was proportional to the
expression levels of PKCδ obtained by infecting cells with different MOIs of the
PKCδ AdV. Indeed, infection with an MOI=1 pfu/cell did not cause any significant
PKCδ overexpression and consequently failed to sensitize H1650-M3 cells to erlotinib
(IC50 = 24.2 ± 0.6 µM for PKCδ Adv; IC50 = 24.7 ± 2.0 µM for LacZ Adv). On the other
hand, an MOI=10 pfu/cell caused a noticeable shift to the left in viability dose-response
for the erlotinib (IC50 = 8.7± 1.9 µM for PKCδ Adv; IC50 = 26.4 ±0.4 µM for LacZ Adv).
At higher MOIs, the sensitivity of H1650-M3 cells was essentially similar to that
observed in control (LacZ-infected) H1650 cells (MOI=30: IC50 = 6.3 ± 0.5 µM for
PKCδ Adv; IC50 = 22.2 ± 0.4 µM for LacZ Adv; MOI=100: IC50 = 4.5 ± 0.4 µM for
PKCδ Adv; IC50 = 19.5 ± 1.0 µM for LacZ Adv. These results indicate that PKCδ downregulation contributes to erlotinib resistance of NSCLC cells.
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Previous studies have shown that overexpression of one PKC isozyme could alter
the expression PKC family member. For example, overexpression of PKCα could alter
the expression of PKCδ, PKCε and PKCι in different cellular models [107, 154, 198]. As
erlotinib-resistant H1650 cells display PKCα overexpression and PKCδ down-regulation
relative to the parental cell line, we asked if there was a mutual regulation controlling
these changes. To test our hypothesis, we either overexpressed PKCα or depleted PKCδ
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Figure 2.3 PKCδ alters the sensitivity of H1650-M3 cells to erlotinib
(A) Overexpression of PKCδ after 5 days was confirmed using Western blot. (B) H1650M3 cells were infected with either LacZ Adv or PKCδ Adv at different MOI. 48 h after
infection, H1650-M3-PKCδ cells were seeded in 96-well plates, and treated with
erlotinib at indicated concentrations 24 h later. Cell viability was determined the
following day using MTS.
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Interestingly PKCα overexpression by adenoviral means reduced the expression
of PKCδ mRNA and protein levels. These effects were proportional to the levels of
PKCα overexpression achieved by using increased MOIs of the PKCα Adv (Fig. 2.4A
and 2.4B). In the next set of experiments we assessed if down-regulation of PKCδ alters
PKCα expression levels. PKCδ expression was silenced from parental H1650 cells using
RNAi and PKCα levels were determined by Western blot. As shown in Fig. 2.4C, both
control and PKCδ silenced H1650 cells display similar PKCα levels. Furthermore, we
overexpressed PKCδ in erlotinib-resistant M3-H1650 cells, and expression levels of
PKCα essentially remain unchanged (Fig. 2.4D). These results argue for a unidirectional
cross-talk between PKCs whereby overexpression of PKCα in NSCLC cells contributed
to the down-regulation of PKCδ, but PKCδ levels were unable to influence those of
PKCα.
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Figure 2.4 PKCα modulates the expression of PKCδ
(A) H1650 cells were infected with either LacZ Adv (100 MOI) or PKCα Adv at
different MOI. Changes in PKCα, and PKCδ mRNA were determined by qPCR 72 h
after infection. Results are expressed as fold-change relative to LacZ Adv. (B) Protein
levels of PKCα and PKCδ were analyzed by Western blot 72 h after infection. (C)
Parental H1650 cells were transfected with either PKCδ RNAi dupleses (δ1 or δ2) or
non-target control (NTC) RNAi duplexes. Expression of PKCα and PKCδ were analyzed
by Western blot after 72 h. (D) H1650-M3 cells were infected with either LacZ Adv or
PKCδ Adv (100 MOI). The expressions of PKCδ and PKCα were measured in H1650,
H1650-M3 and PKCδ overexpressing H1650-M3 cells after 96 h using Western blot.
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PKCα is required for the maintenance of H1650-M3 cell mesenchymal phenotype
Erlotinib-resistant H1650 cells exhibit mesenchymal properties, a phenotype that
is mediated by TGF-β [212]. The mesenchymal phenotype is a hallmark of cancer stem
cells exhibiting aggressive phenotype [182]. A recent study in breast cancer showed that
PKCα is up-regulated in cells that had undergone EMT [181], thus we speculated that
this kinase might contribute to the maintenance of the mesenchymal phenotype of
erlotinib-resistant cells. Parental H1650 cells were sorted into CD44high/CD24low and
CD44low/CD24high enriched populations, and PKCα mRNA levels were determined in
both populations using qPCR. This experiment shows that PKCα mRNA levels were
elevated in the CD44high/CD24low cells (Fig. 2.5A).
As shown in a previous study [212], H1650-M3 cells display markedly elevated
levels of genes associated with EMT, including vimentin, Snail, Twist, and Zeb as well as
reduced levels of E-cadherin. To establish a potential involvement of PKCα upregulation in the mesenchymal phenotype of H1650-M3 cells, we examined the
expression of EMT markers after silencing PKCα. Notably, PKCα RNAi depletion
markedly reduced vimentin, Snail, Twist, and Zeb levels, suggesting that this kinase
mediates the induction of these EMT genes. Levels of the epithelial marker E-cadherin
remained unaffected (Fig. 2.5B). For those markers that could be readily detected by
Western blot (vimentin and Snail), changes were also validated at the protein level (Fig.
2.5C). Despite the PKCα requirement for the expression of EMT markers, it became
apparent that overexpression of this kinase in the parental H1650 cells was not sufficient
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to induce these EMT genes, as determined by qPCR 72 h after infection with increased
MOIs of the PKCα Adv (Fig. 2.5D). No changes were observed even 1 week after PKCα
Adv infection. Altogether, these results indicate that PKCα is required for the
maintenance of mesenchymal phenotype of erlotinib-resistant cells, however its
overexpression is insufficient to induce this phenotypic change.
Next, we set to explore whether PKCδ has a role in the expression of genes
associated with EMT transition. As PKCδ is down-regulated in H1650-M3 cells, we
adenovirally overexpressed PKCδ in these cells and assessed the expression of EMT
markers by qPCR. Unlike PKCα silencing, ectopic overexpression of PKCδ in H1650M3 cells did not change the expression of vimentin, Twist, or Zeb2, although a reduction
in Snail levels could be observed. Likewise, PKCδ overexpression did not affect Ecadherin mRNA levels (Fig. 2.5E). Consistent with these results, no changes in protein
levels for E-cadherin and vimentin could be observed (Fig. 2.5F). We also found that
PKCδ RNAi depletion from parental H1650 cells failed to change the expression of EMT
markers (Fig. 2.5G). Therefore, the involvement of PKCδ is only confined to erlotinib
resistance but not to EMT.

53

CD44 APC 660/20 RedA

A
Relative mRNA
levels

10

Relative mRNA
levels
Relative mRNA
levels

B

6
4
2
PKC!

80

15

60

10

40

5

20
0

0

Snail

Twist

20
15

H1650 M3

M3
M3
si!1 si!"

101
100
101
102
103
104
105
150

CD44

Ecadherin

Zeb2

100

10
5
0

CD24

PKC"

Vimentin

PKC!

20

5
4
3
2
1
0

8

0

CD24 PE 575/26 GreenA

CD44low/CD24high
CD44high/CD24low

50
H1650 M3

54

M3 M3
si!1 si!"

0
H1650 M3 M3 M3
si!1 si!"

H

16
50
M
3
M
3
si
M !1
3
si
!
#

16
5
M 0
3
M
3
si
M !1
3
si
!
#

H

C

PKC!

Vimentin

PKC"

Snail

Ecadherin

Vinculin

D
Vimentin

H1650
H1650 LacZ (300 MOI)
H1650 PKC!"#10 MOI)
H1650 PKC!"#30 MOI)
H1650 PKC! (100 MOI)
H1650 PKC! (300 MOI)

Snail
Ecadherin
PKC!
0.1

1
10
100 1000
Relative mRNA level

E

Zeb2
Vimentin
Twist
Snail
Ecadherin
PKC"
PKC!
0

M3
M3PKC"

1

2

3

4

5

Relative mRNA level

55

6

F

H1650 M3 M3PKC!
PKC!

G

NTC si!1 si!"
PKC!

Ecadherin

Ecadherin

Vimentin

Snail

Vinculin

Vinculin

Figure 2.5 PKCα is required but not sufficient for maintenance of mesenchymal
phenotype
(A) Parental H1650 cells were analyzed by flow cytometry for CD44 and CD24
expressions. Following the analysis, cells were sorted into CD44high/CD24low and
CD44low/CD24high sub-populations and the levels of PKCα and PKCδ mRNA were
compared by qPCR in each population. (B) H1650-M3 cells were transfected with either
PKCα RNAi (α1 or α2) or non-target control (NTC) RNAi duplexes. After 72 h, RNA
was extracted for qPCR analysis of selected genes associated with epithelial or
mesenchymal phenotypes. Results are expressed as fold-change relative to parental
H1650 cells. (C) Proteins were extracted after PKCα RNAi depletion and levels of
epithelial and mesenchymal markers were determined using Western blot. (D) H1650
cells were infected with either LacZ Adv (100 MOI) or PKCα Adv at different MOI.
After a week, expression mesenchymal genes and E-cadherin were determined using
qPCR. (E) H1650-M3 cells were infected with either LacZ Adv or PKCδ Adv (100
MOI). After 96 h, the mRNA level of mesenchymal associated genes was measured. (F)
Western blot showing the protein expression of PKCδ, Vimentin and E-cadherin. (G)
Parental H1650 cells were transfected with either PKCδ RNAi (δ1 or δ2) or non-target
control (NTC) RNAi duplexes. Expression of PKCδ, E-cadherin and Snail were analyzed
by Western blot after 72 h.

56

PKCα up-regulation in erlotinib-resistant cells is mediated by TGF-β
TGF-β has been widely implicated in EMT in multiple cancer types [35, 88, 201].
Activation of the TGF-β signaling pathway mediates EMT and erlotinib resistance in
H1650 cells [212]. Based on this premise, we sought to establish if a causal relationship
exists between TGF-β signaling and PKCα expression. H1650-M3 cells were treated
with the TGF-β inhibitor LY2109761 for different times, and its efficacy to inhibit TGFβ signaling was confirmed by its ability to reduce Smad2 phosphorylation (data not
shown). Notably, the TGF-β inhibitor caused a time dependent reduction in PKCα
mRNA levels (Fig. 2.6A). This effect was noticeable at the protein level particularly 48
and 72 h after LY2109761 treatment (Fig. 2.6B). Furthermore, we treated parental H1650
cells with recombinant TGF-β for different times, and found that it caused a significant
PKCα up-regulation both at mRNA and protein levels. This effect was quiet remarkable
after long term treatment with TGF-β (Fig. 2.6C and 2.6D). Therefore, TGF-β signaling
is implicated in the overexpression of PKCα in erlotinib-resistant cells.
Lastly, we sought to establish an association between PKCα up-regulation and
TGF-β signaling in the induction of the mesenchymal phenotype. H1650 cells were
infected with the PKCα Adv (or LacZ Adv as a control) and then subject to TGF-β
treatment. mRNA was extracted a week after treatment and EMT markers were
determined by qPCR. As shown in Fig. 2.6E, overexpression of PKCα potentiated the
induction of the mesenchymal genes vimentin, Snail and Twist, by TGF-β .
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Figure 2.6 TGF-β signaling controls expression of PKCα in erlotinib-resistant cells
(A) Erlotinib-resistant (H1650-M3) cells were plated overnight and treated with a TGF-β
inhibitor (LY2109761, 5 µM) for the indicated times. PKCα mRNA levels were
measured by qPCR. (B) Protein levels of PKCα were determined by Western blot and
densitometric analysis was carried out as described before. (C) Parental H1650 cells were
cultured on a 60 mm plate and treated with TGF-β (5 ηg/ml) for 24 h, 48 h, 1 week or 2
weeks. PKCα protein levels were determined using Western blot. (D) mRNA levels of
PKCα were determined after 6 h and 2 weeks of TGF-β treatment. (E) H1650 cells were
infected with either LacZ Adv or PKCα Adv (30 MOI). 24 h after infection, H1650PKCα cells were treated with TGF-β (5 ηg/ml) for a week. mRNA expressions for
PKCα and genes associated with epithelial and mesenchymal phenotypes were assessed
using qPCR.
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2.3 Discussion
Tumors harboring activating mutations of EGFR depend on the oncogene to
maintain their malignant proliferation and survival. TKIs such as erlotinib have been
effective for treatment of NSCLC patients with EGFR activating mutations. However,
many of the patients exposed to erlotinib develop acquired drug resistance to the
targeted-molecular therapy. One of the main causes of drug resistance is a relief of EGFR
addiction and dependence on other oncogenic alterations. Characterization of signaling
pathways implicated in the new oncogenic alteration is important to determine an
effective therapy for patients with acquired resistance. PKC isozymes have been
recognized as key effectors of known oncogenes such as c-MET, KRAS and TGF-β,
which are implicated in induction of drug resistance [14, 21, 132]. Moreover, phorbol
esters, which are known activators of PKCs, have been shown to induce multidrug
resistance in cellular and xenografts models. In this regard, early studies in breast and
small cell lung cancer have identified a role of phorbol esters in inducing phosphorylation
of drug efflux pumps leading to reduced drug accumulation [48].
Here we present evidence for the role of PKC isozymes in the mechanisms of
erlotinib resistance and epithelial-mesenchymal transition in NSCLC cells. Using
isogenic cell models, we found correlations between alteration in PKC isozymes
expressions and induction of resistance to erlotinib. Indeed, erlotinib-resistant H1650-M3
cells exhibit high levels of PKCα while PKCδ expression was down-regulated. Although
this is the first evidence for the involvement of the two PKC isozymes in resistance to
molecular-targeted therapy, altered expressions of PKCα and PKCδ have been detected
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in several cancer cells resistant to endocrine therapy and chemotherapeutic drugs.
Elevation of PKCα expression or activity has been reported in pancreatic, colon, glioma
and gastric cancer cells resistant to chemotherapeutic drugs such as cisplatin, doxorubicin
and vincristine [30, 114, 207, 220] Interestingly, comparable to what is observed in
erlotinib-resistant cells, continuous exposure of MCF-7 cells to Tamoxifen rendered high
levels of PKCα and down-regulation of PKCδ [102].
Studies have indicated the importance of PKCα overexpression in protecting
cancer cells against drug-induced cell death. PKCα overexpression in colon cancer cells
attenuated doxorubicin induced apoptosis by elevating phosphorylation of Bcl-2, Bad and
decreasing PARP cleavage PKCα has also been shown to regulate the cell cycle kinase
cyclin D in drug resistant pancreatic cancer cells. More importantly, in several drug
resistant cancer models, PKCα overexpression has been associated with reduced drug
resistance by inducing increased expression and phosphorylation of a drug efflux pump,
P-gp, encoded by the multidrug resistant gene 1 (MDR1) [99]. The functional importance
of PKCα overexpression has further been demonstrated by using pharmacological
inhibitors and RNA interference. Inhibition of PKCα using Gö6976 restored the
sensitivity of pancreatic cancer cells to chemotherapeutic drugs [30]. Blocking PKCα by
RNAi interference also reversed drug resistance in ovarian cancer cells [220]. In our
study, we found that RNAi depletion or inhibition of PKCα using Gö6976 sensitize
erlotinib-resistant NSCLC cells to the TKI.
Overexpression of one PKC isozyme could lead to altered expression of other
members of the PKC family and there are several potential reasons suggested for the
62

observed phenomenon. Overexpression of one PKC isozyme could compete for
proteases, which are required for degradation of other PKCs. Alternatively crossphosphorylation between PKCs, could change the sensitivity to proteolysis and result in
mRNA stability [154]. In other cases, the alteration in more than one PKC isozymes
occurs as cross-regulation by several PKCs is required to achieve a full transformed
phenotype. For example, as shown in MCF-7 cells, overexpression of PKCα resulted in
down-regulation of endogenous PKCδ and reduction in PKCδ expression as well as high
levels of PKCα were found to be important for the phenotypic changes observed in
MCF-7-PKCα cells [198]. Similar phenomenon was observed in the H1650 where
overexpression of PKCα resulted in down-regulation of PKCδ comparable to the levels
in erlotinib-resistant H1650-M3 cells. Moreover, we found that the overexpression of
PKCα as well as down-regulation of PKCδ were important to maintain erlotinib
resistance in H1650-M3 cells.
As previously characterized, H1650-M3 cells have elevated expression of genes
associated with EMT and display morphological changes that are reminiscent of
mesenchymal phenotype. Interestingly, the parental erlotinib naive cells were shown to
possess a subpopulation of cells that are mesenchymal, erlotinib-resistant and similar to
H1650-M3 cells [212], indicating that H1560-M3 cells were potentially generated
through a selection process that favors the survival of cells that utilize alternate
mechanisms to overcome drug-induced death. Certainly the identification of these
mechanisms is crucial to effectively target drug-resistant tumors. PKCα has been
implicated in the survival of cancer stem cells, which are known to arise during EMT
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[181]. Inhibition of PKCα was shown to preferentially induce apoptosis of breast cancer
stem cells. Additionally, elevated PKCα expression was found in a subpopulation of
normal mammary epithelial cells enriched with a mesenchymal surface marker CD44
[181]. Similarly, our results indicate a correlation between enrichment of mesenchymal
phenotype and PKCα expression. Inhibition of PKCα in H1650-M3 cells also led to
inhibition of genes associated with mesenchymal phenotype. Interestingly, although
exposure to erlotinib resulted in differential expression of EMT markers including upregulation of mesenchymal genes such as vimentin, snail, twist and Zeb2, and
downregulation of the epithelial marker E-cadherin, the effect of inhibiting PKCα was
limited to the genes associated with mesenchymal phenotype underscoring its role in the
maintenance of this phenotype.
Several factors could regulate the expression of PKCα in NSCLC cells. As TGFβ signaling was shown to be sufficient and required for the induction of erlotinib
resistance and EMT in H1650-M3 cells [212], we explored a potential relationship
between TGF-β and PKCα. Inhibition of TGF-β signaling blocked the expression of
PKCα in H1650-M3 cells. Moreover, treatment with TGF-β increased the expression of
PKCα in the parental erlotinib sensitive epithelial cells indicating that in the process of
acquiring an aggressive phenotype, TGF-β up-regulated the expression of PKCα.
Although the promoter region of PKCα does not consist of a TGF-β binding region,
studies have identified PKCα as a TGF-β target gene. For example, gene profiling in
A549 lung adenocarcinoma cell lines has shown that Prkca is one of the genes upregulated by TGF-β treatment [142]. In conclusion our results provide evidence for a role
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of PKCs in acquired resistance and EMT and suggest a potential use of PKCα inhibitors
to specifically target mesenchymal tumors including cancer stem cells that are resistant to
therapy.
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2.4 Materials and Methods
Reagents
Erlotinib hydrolchloride was purchased from Santa Cruz (Santa Cruz, CA). The
pan-PKC inhibitor GF109203X was purchased from Enzo Life Sciences (Plymouth
Meeting, PA). The cPKC inhibitor Gö6976 was obtained from LC laboratories (Woburn,
MA). The CellTiter 96® AQueous One Solution Cell Proliferation Assay kit was
purchased from Promega.

Cell Culture
H1650 and H1650-M3 cell lines were generated in the laboratory of Dr. Raffaella
Sordella (Cold Springs Harbor, NY) [212] and cultured in RPMI 1640 medium
supplemented with 5 % FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. Cells
were maintained at 37 °C in a humidified 5 % CO2 atmosphere.

Real-time PCR
Total RNA was extracted from subconfluent cell cultures using RNeasy Kit from
Qiagen (Valencia, CA). Total RNA (1 µg) was reverse transcribed to cDNA using
Taqman reverse transcription reagent kit in a total volume of 20 µl (Applied Biosystems,
Branchburg, NJ). Real-time quantitative PCR (qPCR) was performed using an ABI
PRISM 7700 detection system. The reaction was carried out in triplicate containing
TaqMan universal PCR MasterMix (Applied Biosystems), target primers (300 nM),
fluorescent probe (200 nM), and 4 µl of transcribed cDNA (6X dilution). Taqman
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primers 5’end-labeled with 6-carboxyfluorescein (FAM) for PKCα, PKCδ, E-cadherin,
Snail, Twist1, Vimentin, Zeb2 and 18S rRNA (housekeeping gene) were used. PCR
product amplification was continuously monitored using the sequence detection system
software version 1.7 (Applied Biosystems). Triplicate circle threshold (Ct) values were
averaged and normalized to an average 18S Ct value to calculate the ΔCt. The Δ (ΔCt)
was determined by subtracting the control ΔCt value from the experimental ΔCt value.
Fold change were expressed as 2-ΔΔCt.

Western blot
Cells were harvested in lysis buffer (125 mM Tris-HCl, pH 6.8, 50% glycerol, 4%
SDS, 0.08% bromophenol blue, and 20 % β-mercaptoethanol). Samples were resolved in
10 % SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore,
Bedford, MD). After blocking with 5 % milk in 1 % Tween 20/PBS, membranes were
incubated with the primary antibody. The following primary antibodies were used: antiPKCα (EMD Millipore Corp., Billerica, MA), anti-PKCε (Santa Cruz Biotechnology,
Santa Cruz, CA), anti-PKCι (Abcam, Cambridge, MA), anti-PKCδ, anti-vimentin, antiE-cadherin, anti-Snail, anti-phospho-Smad2 (Cell Signaling Technology, Danvers, MA),
and anti-vinculin (Sigma-Aldrich, St. Louis, MO). Either anti-mouse or anti-rabbit
secondary antibodies conjugated with horseradish peroxidase (Bio-Rad, Hercules, CA)
were used. Bands were visualized by the enhanced chemiluminescence Western blotting
detection system, and images were captured using the FujiFILM LAS-3000 system.
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RNA interference
RNAi duplexes for silencing PKCα were purchased from Dharmacon (Lafayette,
CO). The target sequences were: PKCα RNAi #1; CCAUCCGCUCCACACUAAA;
PKCα RNAi # 2; GAACAAGGAAUGACUU [134].

Control silencer RNAi was

purchased from Ambion (Austin, TX). Cells were transfected with RNAi duplexes (25
nM) using Lipofectamine RNAi/MAX and used for the indicated experiments.

Adenoviral infections
Cells were infected with adenoviruses (Advs) for PKCα, PKCδ, or LacZ (control)
using different multiplicities of infection (MOIs) as previously described [184] . The
infection was carried out in RPMI 1640 medium supplemented with 2 % FBS. Complete
medium was added 4 h later. Experiments were carried out 72-96 h later, as indicated.

Cell viability assay
Cell viability was determined using the CellTiter 96® AQueous One Solution
Cell Proliferation Assay kit, a colorimetric assay that contains MTS (3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
and phenazine ethosulfate (PES) with enhanced chemical stability. Cells seeded into 96well plates (1 × 104 cells/well) were treated with different concentrations of erlotinib for
different times, as indicated. One h after addition of the One Solution Reagent,
absorbance was recorded at 490 nm using a 96-well plate reader.
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Flow Cytometry
Subconfluent H1650 cells were detached using 0.02 % EDTA in PBS and
washed, pelleted and resuspended in FACS buffer (PBS pH 7.2, 0.2 % bovine serum
albumin). 5 ×106 cells were co-stained with phycoerythrin-conjugated anti-human CD24
and allophycocyanin-conjugated anti-human CD44 (BD Biosciences, San Jose, CA)
antibodies. Labeling was performed for 1 h at room temperature in the dark. Labeled cells
were washed three times with the FACS buffer and sorted using a BD FACS Aria II cell
sorter. Gates were set either at CD44/CD24 high or low expressions, and subpopulation
of cells were collected in FACS buffer for RNA extraction.

Statistical Analysis
All statistical analyses were done using GraphPad Prism v5.03 (GraphPad
Software, Inc., San Diego, CA). A p value < 0.05 was considered statistically significant.
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CHAPTER 3: PKCα signaling is required for NF-κΒ
activation in NSCLC cells
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3.1 Introduction
Inflammation is a part of innate immunity in response to physiological and
environmental stimuli [109]. However, persistent inflammation causes prolonged
activation of immune cells, which results in tissue damage and risks that lead to
neoplasia. Induction of proinflammatory cytokines, such as TNFα or IL-1β activates the
transcription factor NF-κΒ through the canonical pathway. The activation process
involves various signaling molecules and converges on the IκB kinase (IKK) complex,
which consists of two closely related kinases, IKKα and IKKβ, and the regulatory unit
NEMO. Phosphorylation and activation of this complex, particularly IKKβ, recruits and
phosphorylates the NF-κΒ inhibitor protein, IκΒα, at serine residues followed by
ubiquitination and subsequent degradation of the inhibitor protein. Loss of IκΒα releases
NF-κΒ, which then translocate to the nucleus and drives transcription of multitude of
genes. NF-κΒ is an important player in tumor progression as it is activated in chronic
inflammation. In addition to the tumor-promoting role of NF-κΒ that involves stimulation
of cell cycle progression, inhibition of apoptosis, increased invasive growth, and elevated
resistance to radiation and chemotherapy, this transcription factor also participates in
tumor initiation. For example, activated NF-κΒ in macrophages and neutrophils
stimulates the production of reactive oxygen species (ROS) by inducing the transcription
of inducible nitric oxide synthase (iNOS). ROS induce DNA damage and initiates lesions
in the surrounding cells, thus contributing to tumorigenesis [74].
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IL-1β is a pro-inflammatory cytokine that triggers a cascade of inflammatory
reactions through NF-κB dependent expression of genes, which also have implications in
cancer progression. IL-1β is produced as an inactive precursor, pro-IL-1β, in response to
injuries or infections. Following induction of pro-IL-1β expression, the precursor is
loaded onto a multi-protein scaffold complex called the inflammasome, where it is
cleaved by the pro-inflammatory protease caspase-1 and released out of the cells. The
release of IL-1β into the tumor microenvironment leads to activation of inflammatory
signals in the tumor cell and its stroma [167]. Notably, high levels of IL-1β are found in
serum from patients with chronic lung infections and lung cancer [16, 223]. Moreover,
exposure of lung epithelial cells to IL-1β increases expression of cyclooxygenases,
metalloproteases and growth factors known to induce proliferation, angiogenesis and
invasive phenotype of lung cancer cells [31, 164].
PKCs isozymes are pleiotropic regulators of cellular processes in lung cancer.
Nevertheless, their functions are highly dependent on the cell type, occurrence of
oncogenic mutations and stimuli. In the present study, we established PKCα signaling as
an important component of NF-κΒ activation in NSCLC cells. Depletion of PKCα
significantly attenuated IL-1β induced NF-κΒ pathway activation, including IκΒ
phosphorylation, as well as nuclear translocation and DNA binding. Overall, these
findings underscore the importance of PKCα signaling in the pathogenesis of lung
cancer.
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3.2 Results
PKCs regulate NF-κΒ activation in NSCLC cells
Tumor infiltration of immune cells due to chronic inflammation marks the
progression of many advanced cancer types. NF-κΒ is a well-known mediator of
responses by proinflammatory cytokines such as TNFα and IL-1β in NSCLC. As PKC
signaling has been linked to NF-κΒ activation in several cancer types [54, 124], we set
out to determine if PKC signaling contributes to NF-κΒ activation in response to
inflammatory cytokines in NSCLC. We first measured NF-κΒ activation in H460 cells in
response to cytokines (TNFα, IL-1β) known to induce NF-κΒ transcriptional activity
using a luciferase reporter assay. Stimulation of H460 cells with IL-1β or TNFα led to
an elevation in NF-κΒ luciferase activity with the highest luciferase activity being
measured 6 h after IL-1β treatment. Next, to establish the role of PKCs in IL-1β or
TNFα-induced NF-κΒ activation, we employed the pan PKC inhibitor GF1090203X to
determine the effect of NF-κΒ transcriptional activity. Pre-treatment GF1090203X
markedly attenuated cytokine-induced transcriptional activation of NF-κΒ. Notably,
GF1090203X was most effective in inhibiting the activation of NF-κΒ in response to IL1β than TNFα or PMA (Fig. 3.1).
PKCα is required for IL-1B mediated NF-κΒ activation
PKCα and PKCε are found to be overexpressed in H460 cells compared to the
normal lung epithelial cells (data not shown). As phosphorylation of IκΒα is a critical
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Figure 3.1 PKCs are implicated in NF-κβ activation
H460 cells were co-transfected with NF-κΒ firefly luciferase reporter and pTK-Renilla
plasmid. 24 h later, cells were pre-treated with GF1090203X (5 µM, 1 h) followed by
treatment with TNFα (10 ng/mL, 6 h), IL-1β (10 ng/mL, 6 h) or vehicle.
step in the activation of the NF-κΒ pathway, we next assessed the effect of PKCα or
PKCε inhibition on phospho-IκΒα levels. IL-1β-induced IκΒα phosphorylation was
significantly attenuated by pre-treatment with either GF1090203X or a classical PKC
inhibitor, Gö6976, thus implicating the involvement of PKCα in IL-1β induced IκΒα
phosphorylation (Fig. 3.2A). To unambiguously demonstrate the involvement of PKCα
in regulating IκΒα phosphorylation, we used two different RNAi duplexes to silence
PKCα expression from H460 cells. PKCα depletion significantly reduced IL-1β-induced
IκΒ phosphorylation and prevented IκΒ degradation (Fig. 3.2B).
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Figure 3.2 PKCα mediates phosphorylation of IκΒα
(A) H460 cells were pre-treated with GF1090203X (5 µM, 1 h) followed by treatment
with IL-1β (10 ng/mL, 5 min) and phosphorylated IκΒα levels were determined by
Western blot. (B) Cells were transfected with either PKCα RNAi duplexes (α1 or α2) or
non-target control (NTC). After 48 h, cells were treated with IL-1β (10 ng/mL) for 5 min
and total and phosphorylated IκΒα levels were determined by Western blot.
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To specifically ascertain the role of PKCε in IL-1β-induced IκΒα
phosphorylation, H460 cells were pre-treated with εV1-2, a selective PKCε inhibitor
fused with the carrier peptide Tat, which blocks PKCε translocation to membrane
compartments and therefore prevents its activation. Contrary to the effect of Gö6976,
εV1-2 had no effect on phospho-IκΒα levels compared to the Tat peptide control (Fig.
3.3A). We also used RNAi for PKCε and PKCδ to rule out the involvement of the nPKCs
in the NF-κΒ activation in H460 cells (Fig. 3.3B). Similar results were observed in
H1975 cells (Fig. 3.3C). To further assess the role of PKCα in NF-κΒ activation in
response to IL-1β, we took advantage of the NF-κΒ luciferase reporter. As shown in Fig.
3.4, luciferase activity induced by IL-1β was drastically reduced in PKCα-depleted H460
cells.
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Figure 3.3 nPKCs do not mediate IL-1β-induced IκΒα Phosphorylation
(A) H460 cells were pre-treated either with the PKCε specific inhibitor, εv1-2 (5 µM, 1
h) or Tat carrier peptide and phosphorylation of IκΒ was determined by Western blot. (B)
Cells were transfected either with PKCα (α1 or α2), PKCε (ε6 or ε8), PKCδ (δ1 or δ2)
RNAi duplexes, or non-target control (NTC). After 48 h, cells were treated with IL-1β
(10 ng/mL) for 5 min and total and phosphorylated IκΒα levels were determined by
Western blot. (C) The experiments in Fig 3.3B were repeated in H1975 cells.
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Figure 3.4 PKCα controls NF-κΒ promoter activity
H460 cells were transfected with either PKCα RNAi duplexes (α1 or α2) or non-target
control (NTC). 24 h after PKCα NTC or RNAi transfection, H460 cells were cotransfected with NF-κΒ firefly luciferase reporter and pTK-Renilla plasmid. The
following day, cells were stimulated with IL-1β (10 ng/mL) and luciferase activity was
determined after 6 h using the dual luciferase reporter assay.
PKCα is critical for NF-κΒ nuclear translocation and DNA binding
Transcriptional regulation by NF-κΒ also depends on its translocation from the
cytosol to the nucleus following IκΒα degradation. As activation of the NF-κΒ pathway
leads to the relocalization of NF-κβ to the nucleus, we speculated that alteration of PKCα
signaling may affect this NF-κΒ intracellular mobilization. We used a cell fractionation
approach to determine the effect of PKCα on IL-1β induced NF-κΒ nuclear translocation
in H460 cells. As expected, IL-1β promoted the translocation of NF-κΒ from the
cytosolic to nuclear compartments. This accumulation of NF-κΒ in the nuclear fraction
was completely blocked upon PKCα RNAi depletion (Fig. 3.5A). We then set out to
identify whether IL-1β-induced NF-κΒ DNA binding involves PKCα signaling. To
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address this issue we used electrophoretic mobility shift assay (EMSA) as an approach.
As shown in Fig. 3.5B, stimulation with IL-1β promotes an elevation in NF-κΒ DNA
binding activity in H460 cells nuclear extracts. Remarkably, this DNA binding activity
was attenuated in nuclear extracts from PKCα-depleted H460 cells. Taken together these
results confirm the requirement of PKCα in NF-κΒ activation in response to IL-1β in
NSCLC cells.
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Figure 3.5 PKCα is critical for NF-κΒ nuclear translocation and DNA binding
(A) Localization of NF-κΒ was assessed in cysosolic and nuclear fractions after 1 h of
IL-1β (10 ng/mL) stimulation in control or PKCα depleted H460 cells using Western
blot. ATF2 and vinculin were used as loading controls for nuclear and cytoplasmic
fractions respectively. (B) The effect of PKCα depletion on NF-κΒ DNA binding was
measured using EMSA. The nuclear fractions were extracted 1 h after IL-1β (10 ng/mL)
stimulation or vehicle treatment. “F” represents free probe.
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PKCα overexpression in normal lung epithelial cells enhances NF-κΒ activation
As PKCα was found to play a significant role in IL-1β-induced NF-κΒ activation
in lung cancer cells, we speculated that it could also have implications upon
overexpression in normal lung epithelial cells. For these experiments, we used human
bronchial epithelial cells (HBEC), a model of “normal” immortalized cells. HBEC cells
were infected with different MOIs of a PKCα Adv, and LacZ Adv was used as a control.
We observed that overexpression of PKCα potentiated IL-1β induced phospho-IκΒ levels
(Fig. 3.6A). To further prove our hypothesis, we transfected PKCα overexpressing
HBEC cells with the NF-κΒ luciferase reporter as shown in Fig. 3.6B, overexpression of
PKCα by itself enhanced NF-κΒ luciferase activity. As a complementary approach, we
measured NF-κΒ DNA binding activity in response to IL-1β in PKCα overexpressing
HBEC cells. As expected, PKCα overexpression significantly increased NF-κΒ DNA
binding in response to IL-1β (Fig. 3.6C).
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Figure 3.6 Overexpression of PKCα potentiates IL-1β induced NF-κβ activation in
normal lung epithelial cells
HBEC cells were infected with either LacZ Adv (100 MOI) or PKCα Adv at different
MOI for 72 h and treated with IL-1β (1 ng/mL, 5 min). (A) Protein levels of PKCα and
phosphorylation of IκΒα were analyzed by Western blot after 5 min of IL-1β
stimulation. (B) PKCα overexpressing HBEC cells were co-transfected with NF-κΒ
firefly luciferase reporter and pTK-Renilla plasmid. 24 h later, cells were treated with IL1β (1ng/mL, 6 h) and luciferase activity was determined. (C) Nuclear lysates of PKCα
overexpressing HBEC cells treated with IL-1β (1 ng/mL) for 5 min, were extracted and
NF-κΒ DNA binding was analyzed by EMSA.
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PKCα regulates the expression of NF-κΒ target genes in normal lung epithelial and
cancer cells
Activation of NF-κΒ is required for the induction of genes in response to IL-1β.
These genes are associated with survival and motility of lung cancer cells as well as
production of a range of pro-inflammatory signals that contribute to chronic
inflammation. Hence, to assess the functional relevance of PKCα signaling on NF-κΒ
transcriptional activity, we analyzed the effect of altering PKCα expression in both lung
cancer and immortalized “normal” lung epithelial cells. Treatment of H460 cells with IL1β induces COX-2, IL-8 mRNA levels and MMP9 expressions. Interestingly, the
induction in these NF-κΒ regulated genes by IL-1β was essentially abolished in PKCαdepleted H460 cells (Fig 3.7).
Next we overexpressed, we also overexpressed PKCα in HBEC cells using
adenoviral approach. IL-1β stimulation resulted in a marked elevation of COX-2 and
MMP9 mRNA levels in HBEC. PKCα potentiated the induction of COX-2 and MMP9 in
HBEC cells. For IL-8, Il-1b caused a very high induction (~40-fold) in HBEC cell, and
PKCa overexpression was unable to cause additional effect (Fig. 3.8).
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Figure 3.7 PKCα regulates expressions of NF-κΒ target genes in NSCLC cells
H460 cells were transfected with either PKCα RNAi or NTC. After 48 h, cells were
treated with IL-1β (10 ng/ml) and RNA was isolated after 6 h. Gene expression of Cox-2,
MMP9, and IL-8 was analyzed using qPCR.
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Figure 3.8 Overexpression of PKCα potentiates IL-1β-induced expression of NF-κΒ
target genes in NSCLC cells
Normal lung epithelial (HBEC) cells were infected with either LacZ or PKCα Adv (100
MOI) for 72 h and stimulated with IL-1β (10 ng/ ml) for 6 h. RNA was isolated and gene
expression of Cox-2, MMP9, and IL-8 was analyzed using qPCR.
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3.3 Discussion
There are ample reports implicating PKC isozymes in tumorigenesis. However,
the specific contribution of individual PKC isozymes to various cellular processes that
hallmark the initiation and progression of cancer remains only partially understood. This
is also true for lung cancer, where PKC isozymes have been implicated in lung cancer
malignancy, but their individual roles have not been yet fully characterized. In this study,
we investigated whether PKCs are implicated in controling the activation of the NF-κΒ
pathway in NSCLC. Our results show PKCα regulates the various steps required for NFκΒ activation in NSCLC cells. Notably, PKCα depletion impairs NF-κΒ activation as
well as induction of NF-κΒ target genes in response to IL-1β, arguing for an important
role for PKCα in lung cancer progression.
The transcription factor NF-κΒ plays an important role in host immune
mechanisms. During inflammation, binding of pro-inflammatory cytokines such as TNFα
or IL-1β to their respective receptors results in activation of NF-κΒ. Activation of NF-κΒ
is normally associated with acute inflammatory signals that involve chemokine-and
adhesion molecule-mediated recruitment and activation of immune cells, mainly
neutrophils to the site of inflammation. These acute inflammatory signals eliminate
transformed cells and protect the body against cancer risks. However, during chronic
inflammation, the role of NF-κΒ becomes more complex and multifold [13, 71]. On one
hand, continuous induction of pro-inflammatory factors by NF-κΒ during chronic
inflammation results in DNA damage, leading to oncogenic mutations. On the other
hand, to withstand physiological stress caused by chronic inflammation, NF-κΒ promotes
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cell survival and proliferation by regulating the expression of proteins implicated in cell
cycle cycle control (e.g. cyclin D, c-myc) and apoptosis (e.g. IAP, Bcl-2), adding to its
tumorigenic effects [109, 122].
The advanced lung cancer inflammation index (ALI) is used as a prognostic and
treatment outcome marker for lung cancer patients, thus underscoring the significance of
chronic inflammation in disease pathogenesis [84]. Chronic airway inflammation
contributes to alterations in the bronchial epithelium and the lung microenvironment,
paving a way for lung carcinogenesis. Additionally, lung cancer risk factors such as
chronic obstructive pulmonary disease and chronic pulmonary infections are
characterized by an inflammatory state. Lung tumors also exhibit high levels of
inflammatory mediators such as ROS, cytokines, chemokines, and eicosanoids, which are
associated with cancer initiation [67].
Cigarette smoke is the main cause of oxidative stress and etiological factor that
induces lung cancer by generating ROS leading to tissue destruction. Inflammation due to
smoking results in NF-κΒ dependent up-regulation of pro-inflammatory cytokines
including TNFα, IL-1β, IL-8 and IL-6. Moreover, lung tumors and serum collected from
lung cancer patients are reported to have elevated levels of inflammatory markers (Creactive protein) and chemokines (such as CXCL13 and CCL22) that regulate migration
of lymphocytes to the site of inflammation. Similarly, high levels of the p65 unit of NFκΒ were found in NSCLC compared to the normal lung epithelium [222]. Furthermore,
IKKα/β independent activation of NF-κΒ in response to growth factor receptors was
found to be important for the survival of NSCLC cells and NF-κΒ inhibition attenuated
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the survival of lung cancer cells [29]. In addition to tobacco smoke, other environmental
carcinogens have been causally linked NF-κΒ activation in lung tumors. Urethaneinduced lung tumor development was attenuated in mice with genetic depletion of the
CCR5 chemokine. The CCR5-/- mice were shown to have reduced NF-κΒ activity
compared to the wild type mice [98]. Other studies using mouse models have also shown
the effect of constitutive NF-κΒ activation in the development of pulmonary
adenocarcinoma. Elevated NF-κΒ activity was also reported in KRAS+/-;p53-/- mice and
KRAS-driven lung tumors were attenuated upon NF-κΒ inhibition [10, 118].
Previous studies argued for a connection between PKC isozymes and the NF-κΒ
pathway activation. Initial links in cancer were reported for the aPKCs. Indeed, PKCζ
phosphorylates NF-κΒ upstream kinase IKKβ at ser-177 and ser-181 in response to
TNFα. Additionally PKCζ-/- mice have attenuated RelA binding activity [40]. The other
aPKC isozyme, PKCι also mediates phosphorylation of IKKβ in response to TNFα and
induces NF-κΒ dependent transcription of the IL-6 gene in prostate cancer [106].
Recently, our laboratory identified a key role for PKCε in TNFα-dependent activation of
NF-κΒ in prostate cancer. PKCε was shown to be a part of the TNFRI signaling complex
that leads to NF-κΒ activation [54]. Yet other novel PKC isozyme, PKCδ was reported to
facilitate RelA binding to the promoters of target genes [110]. Activation of the NF-κΒ
pathway is also attributed, in part, to alterations in cPKCs. PKCβ-dependent activation of
NF-κΒ, through modulation of the IKK complex, was found to be crucial for the survival
Chronic lymphocytic leukemia [111, 123]. Using in vitro binding assays, it has been
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shown that PKCα forms a complex with the NF-κΒ upstream kinase, IKK [192].
Additionally PKCα has been shown to interact with IKKβ in response to PMA in 293T
cells. The mechanism for PKCα-dependent NF-κΒ activation was also extended to
phosphorylation of RelA in glioma cells [126]. It has been reported that PKCα mediates
NF-κΒ activation in A549 NSCLC cells in response to TNFα [97].
IL-1β has been shown to induce NF-κB signaling in many cell types. Not
surprisingly, we found that IL-1β treatment activates the NF-κB pathway in H460 cells as
manifested by IκBα phosphorylation and NF-κΒ promoter activity. High levels of IL-1β
are found both in NSCLC cells and within the tumor microenvironment [167].
Additionally, polymorphisms in the IL-1β gene have been associated with increased risk
of NSCLC [223], an indication of the significance of IL-1β-mediated signals in the
pathogenesis of this disease. Here, we showed that depletion of PKCα prevents IL-1βinduced NF-κΒ activation as determined by decreased IκΒα phosphorylation, NF-κΒ
relocalization to the nucleus, NF-κΒ promoter activity, and DNA binding. Studies using
cellular and animal models have shown diverse implications of PKCα signaling in lung
cancer. For example, PKCα up-regulates the cell cycle inhibitor p21 and confers a
senescent phenotype in NSCLC cells [133]. In KRAS mutant mice, PKCα genetic
silencing inhibited oncogene driven lung tumorigenesis [73]. However, there are also
reports of PKCα as a positive regulator of growth and cell motility in NSCLC [31].
PKCα was shown to mediate ERK activation in the RAS signaling cascade [163].
Additionally, aprinocarsen, an antisense oligonucleotide against PKCα, has been used in
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clinical trials for NSCLC patients. This antisense potentiates chemotherapeutic activity of
carboplatin and paclitaxel in phase II trials although it did not enhance the overall
survival of patients in phase III studies [137, 151]. In line with our results, Song et al.
recently showed that inhibition of PKCα led to apoptosis in H460 NSCLC cells [165].
In contrast to the effects of PKCα, neither inhibition of PKCε nor PKCδ
significantly attenuated NF-κΒ activation in NSCLC cells. These findings suggest that
IL-1β-dependent NF-κΒ activation in H460 cells is highly dependent on PKCα. The role
of PKCα in response to IL-1β is not only limited to the cancer cells, but we also observed
elevation of IκΒα phosphorylation and NF-κΒ DNA binding in normal immortalized
lung epithelial cells upon PKCα overexpression. The various biological effects of NF-κΒ
depend on its regulation of target gene expressions. Our findings show that PKCαmediated activation of NF-κΒ by IL-1β results in up-regulation of NF-κΒ responsive
genes involved in cell survival, motility, angiogenesis and inflammation.

Summary
Our results have demonstrated that inhibition of PKCα controls the activation of
the NF-κΒ pathway. PKCα RNAi attenuates IL-1β induced expression of NF-κΒ
responsive genes by decreasing NF-κB transcriptional activity. Overall, these findings
support the notion that distinctive PKCs play a central role in controlling the activation of
the NF-κΒ pathway.
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3.4 Materials and Methods
Cell culture and reagents
The Human lung adenocarcinoma cell lines H460 and H1975 were obtained from
ATTC (Manassas, VA) and cultured in RPMI 1640 medium supplemented with 10 %
FBS (Hyclone, Logan, UT), 100 U/mL penicillin, and 100 µg/mL streptomycin (Life
Technologies, Grand Island, NY). Immortalized human bronchial epithelial cells (HBEC)
were a kind gift from Dr. Trevor Penning (University of Pennsylvania, PA) and were
cultured in KSFM medium supplemented with 0.05 mg/mL bovine pituitary extract and 5
ng/mL EGF purchased from Life Technologies. Cells were maintained at 37°C in a
humidified 5 % CO2 atmosphere. IL-1β was purchased from R&D Systems
(Minneapolis, MN) and used at 1 and 10 ng/mL concentrations. The NF-κΒ firefly
luciferase reporter was a kind gift from Dr. Dave Manning (University of Pennsylvania,
PA). PMA and the cPKC inhibitor Gö6976 were obtained from LC laboratories (Woburn,
MA). The pan-PKC inhibitor GF109203X was procured from Enzo Life Sciences
(Plymouth meeting, PA). The PKCε peptide inhibitor εV1-2 and the carrier peptide Tat
were kind gifts from Dr. Daria Mochyl-Rosen (Stanford University, CA).

Western blots
Western blot analysis was carried out as described on page 68. The following
primary antibodies were used in 1:1000 dilutions: anti-PKCα (EMD Millipore Corp.,
Billerica, MA), anti-PKCε, anti-IκΒα, NF-κΒ p65 (Santa Cruz Biotechnology, Santa
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Cruz, CA), anti-PKCδ, anti-phospho-IκΒα (Cell Signaling Technology, Danvers, MA)
and 1:50,000 dilutions of anti-vinculin (Sigma-Aldrich, St. Louis MO).

Adenoviral infections
Adenoviral infection was carried out as described on page 69.

RNA interference
RNA interference was carried out as described on page 69.

Luciferase Reporter Assay
Cells in 12-well plates (1 × 105 cells/well) were transfected with 0.45 µg of a NFκB firefly luciferase reporter vector and 0.05 µg of the Renilla luciferase expression
vector pRL-TK (Promega, Madison, WI) using Lipofectamine 2000 (Invitrogen). The
DNA/ Lipofectamine 2000 mixture was incubated for 20 minutes and added onto
adherent cells in antibiotic free media. Renilla luciferase vector was used as an internal
control to normalize the transfection efficiency. After 24 h, cells were treated with IL-1β
or vehicle and lysed 6 h later with passive lysis buffer (Promega). Luciferase activity was
measured using the dual-luciferase reporter assay system. The results were expressed as a
ratio of Firefly to Renilla luciferase activities in relative luciferase units (RLU).
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Preparation of nuclear extracts
Cytoplasmic and nuclear extracts were obtained as described previously [155].
Briefly, cells were collected in ice-cold PBS and centrifuged to collect the cell pellets.
Next, cells were resuspended in 250 µl of hypotonic buffer (20 mM HEPES pH 7.9, 10
mM KCl, 1 mM EDTA, 10 % glycerol, 0.2 % Igepal and protease inhibitors) for 10 min.
Lysed cells were centrifuged (2000 × g) for 1 min and the supernatant containing the
cytoplasmic extract was removed. Incubation in hypotonic buffer and centrifugations
were repeated three times to clean the nuclear pellet. The pellet was then resuspended in
100 ml hypertonic buffer (240 mM NaCl, 20 mM HEPES pH 7.9, 10 mM KCl, 1 mM
EDTA, 20 % glycerol, 0.2 % Igepal, and protease inhibitors) and incubated for 30 min at
4°C. After 15 min centrifugation (12000 × g), the supernatant (nuclear extract) was
collected. Both cytoplasmic and nuclear fractions were stored at -80°C until use.

Electrophoretic mobility shift assay (EMSA)
EMSA was carried out as described previously [54]. Briefly, an NF-κB
oligonucleotide probe (5′-agcttGAGGGGATTCCCTTA-3′) was labeled with [α-32P]
dATP using Klenow enzyme. Following purification on a Sephadex G-25 column, the
binding reaction was carried out at 25 °C for 10 min in two sets. The first set contained 5
µg of nuclear proteins, 1 µg of poly (dI-dC), and 106 cpm of labeled probe in a final
volume of 20 µl of binding buffer (10X buffer: 100 mM Tris-HCl pH 7.5, 500 mM NaCl,
50 mM MgCl2, 100 mM EDTA, 10 mM DTT, 1 % Triton X-100, and 50 % glycerol),
while the second set had no nuclear extracts. To show a binding specificity, 50-fold molar
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excess of cold NF-κΒ probe and cold AP-1 probe were used. In the reaction, DNAprotein complexes and unbound probe were separated electrophoretically on 6 % nondenaturing polyacrylamide gels in 0.5X TAE buffer at 200 V. The gel was dried,
followed by autoradiography at -80°C.

RNA isolation and DNA synthesis
RNA isolation and DNA synthesis was carried out as described on page 68.

Real-time PCR
Quantitative real time PCR was carried out as described on page 68. Primers and
fluorogenic probes for PKCα, COX-2, IL-8, MMP9 and 18S were purchased from
Applied Biosystems.

Statistical Analysis
All statistical analyses were done using GraphPad Prism v5.03 (GraphPad
Software, Inc., San Diego, CA). A p value < 0.05 was considered statistically significant.
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Chapter 4: PKCε is required for KRAS-driven lung
tumorigenesis
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4.1 Introduction
KRAS mutations have been identified in approximately 30 % of human lung
adenocarcinomas [41, 87]. KRAS is a member of the RAS small GTPase superfamily and
functions to propagate mitogenic and survival signaling through activation of the MAPK
cascade and PI3K pathway [87] . Thus, RAS mutations result in uncontrolled stimulation
of these signaling pathways and contribute to tumorigenesis. KRAS mutations are
detected in precancerous lesions of lung adenocarcinoma suggesting their role in the
initiation of human lung cancer. Similarly, KRAS mutations were the first molecular
alterations identified in mouse lung tumors and mutation of KRAS is a major early event
in the carcinogenic process of both spontaneous and chemically-induced mouse lung
tumors [83, 202], suggesting that mouse lung tumorigenesis may at least partly model
human lung cancer [129]. Several distinct mouse models that express mutant KRAS at
physiologically normal levels have been generated and show that mutation in this
oncogene is sufficient to drive proliferation and induce the formation of lung
adenocarcinomas [42, 117, 129] . One of these models is the LSL-KRASG12D mice, in
which expression of oncogenic KRASG12D is expressed in the mouse lung upon delivery
of Cre-recombinase. This leads to the development of lung lesions, ranging from atypical
adenomatous hyperplasia to adenocarcinomas. This animal model thus recapitulates the
stages of tumor progression found in NSCLC patients [42].
PKCε is an oncogenic kinase that is dysregulated in many cancers including
NSCLC. Overexpression of PKCε is reported in more than 90 % of primary NSCLC
cancers relative to the normal lung epithelium [7]. Several studies from our laboratory
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underscored the importance of PKCε in lung cancer progression. We previously reported
that PKCε regulates NSCLC cell proliferation, growth and tumorigenicity in nude mice.
Indeed, PKCε RNAi depletion from NSCLC cells reduces anchorage-dependent and
anchorage-independent growth in H358 and A549 cells. Moreover, NSCLC growth in
xenografts in nude mice is substantially impaired by PKCε RNAi depletion or treatment
with the specific PKCε inhibitor εV1-2 [25]. Additionally, our lab has shown that PKCε
is required for the activation of the small GTPase Rac1 and in this way it controls
NSCLC cell motility and invasiveness through regulating the secretion of
metalloproteinases [26]. PKCε also regulates the expression of anti-apoptotic genes such
as Bcl-2 and IAP-2 [12, 63] and controls G1 to S transition in the cell cycle [19, 49].
Additionally, it was previously reported that PKCε depletion sensitizes lung cancer cells
to TRAIL-induced cell death [47].
A growing body of evidence indicates that PKCε is implicated in the initiation
and maintenance of cancer phenotype. Early studies revealed that overexpression of
PKCε in fibroblasts and colonic epithelial cells leads to malignant transformation, which
includes morphological changes, anchorage-independent growth, and increased
tumorigenesis in nude mice [23, 119, 177]. Overexpression of PKCε was found to
transform androgen-dependent prostate cancer cells (LNCaP) to androgen-independent
cancer cells [206]. Additionally, our laboratory showed that overexpression of PKCε in
the mouse prostate is sufficient to induce preneoplastic lesions [18], as well as it
cooperates with PTEN loss to induce prostate adenocarcinoma (unpublished results). In
skin tumor animal models, PKCε overexpression also resulted in hyperplasia,
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hyperkeratosis and the development of skin squamous cell carcinoma in mice treated with
DMBA and a phorbol ester [6]. Thus, it is conceivable that PKCε is implicated in tumor
initiation in lung cancer.
Several studies implicated PKCε in RAS signaling in cancer. PKCε can be
activated by KRAS and is required for RAF-induced cell transformation. Inhibition of
PKCε attenuated NIH 3T3 and Cos-1 cell proliferation similar to dominant negative RAS
and RAF. Moreover, it has been shown that PKCε binds to the RAF kinase domain and
activates its kinase activity by direct phosphorylation [5, 23]. There have been reports
suggesting a link between PKCε and chemically-induced lung carcinogenesis. Indeed,
PKCε depletion was found to suppress cell growth in response to tobacco smoke. At the
mechanistic level, activation of PKCε by ROS generated from tobacco smoke recruits
and phosphorylates the metalloprotease TACE/ADAM-17. Activation of TACE results in
the cleavage of amphiregulin, leading to transactivation of EGFR [100]. PKCε has been
further implicated in the induction of nitric oxide synthase (iNOS), predisposing smokers
to lung cancer [131]. However, a link between PKCε and KRAS tumorigenesis in vivo
still remains to be established.
Here, we examined the requirement for PKCε in lung tumorigenesis in vivo by
using a mouse model. We found that genetic inhibition of PKCε significantly attenuates
KRAS-driven initiation of lung tumors. Additionally, we initiated the generation of an
inducible lung specific PKCε mouse model to study if the overexpression of PKCε is
sufficient to promote the formation of preneoplastic or neoplastic lesions.
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4.2 Results
Generation of KRASG12D; PKCε -/-mice
Oncogenic KRAS-driven mouse models of lung adenocarcinoma have enabled
the study of tumor initiation and progression in vivo. In order to determine whether PKCε
cooperates with KRAS to promote lung tumor formation, we created a mouse model in
which mutated active KRAS was conditionally expressed in PKCε heterozygous or
knockout backgrounds. Previous studies have reported that PKCε knockout mice display
decreased tolerance to alcohol, delayed pain signals and reduced acute cardio protection,
but other than that there are no obvious general abnormalities. Experimental mice were
developed by crossing mice harboring a conditional activated KRAS allele (LSLKRASG12D) with PKCε knockout mice. To achieve the PKCε knockout background, we
first interbred the PKCε-/+ progeny. In the KRAS model, mutant is expressed as
heterozygous whereas homozygotes die in utero [42]. Spontaneous lung tumor initiation
is achieved by intranasal delivery of Cre-recombinase to the lungs using an adenovirus
(Ad-Cre). This leads to removal of the transcriptional stop element and expression of the
oncogenic KRAS. To generate the bitransgenic KRASG12D;PKCε-/- mice, we used two
approaches. The strategies involved crossing KRASG12D;PKCε+/- mice with PKCε-/- mice,
and KRASG12D;PKCε+/- mice with PKCε+/- mice, which had 25 % and 12.5 % chance of
achieving the experimental mice, respectively (Fig. 4.1). The bitransgenic mice appeared
normal at birth and did not display any signs of abnormalities during adulthood. The
deletion of PKCε gene (PRKCE) and the expression of mutant KRAS were verified using
qPCR (Fig. 4.2A and 4.2B).
98

First generation
PKC!-/- ! KRASG12D
Parents allele

Combination

Father

P-P- K+K+

P-K+

Mother

P+P+K+K-

P+K+, P+K-

F1
P+K+
P-K+ P-/+K+/+

P+KP-/+K+/- (50 %)

Second generation
Strategy 1
PKC!-/- ! KRASG12D;PKC!-/+ (F1)
F2
P+K+
P+KP-K+
P-K-

Strategy 2
PKC!-/+ ! KRASG12D;PKC!-/+ (F1)

P-K+
P+/-K+/+
P+/-K-/+
P-/-K+/+
P-/-K-/+

F2
P+K+
P+KP-K+

P+K+
P+/+K+/+
P+/+K-/+
P-/+K+/+

P-K+
P+/-K+/+
P+/-K-/+
P-/-K+/+

P-K-

P-/+K-/+

P-/-K-/+

Figure 4.1 Breeding strategies to generate the KRASG12D;PKCε -/- mice
PKCε knockout mice were crossbred with KRAS mutant mice. The F1 progeny were
crossed either with PKCε heterozygous or PKCε knockout mice to generate the KRAS
mutant in PKCε null background.
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PKC! allele
1

2

3

4

5

PKC! homozygous

606 bp

PKC! WT

500 bp

B

KRAS allele
1

2

3

4

5

G12D

600 bp

WT

507 bp

Figure 4.2 KRASG12D and PKCε mutant mice genotyping
(A) Genomic DNA was extracted and status of wild-type, heterozygous or homozygous
PKCε allele was assessed by PCR. (B) Status of wild-type or mutant KRAS allele was
assessed by PCR.
Genetic ablation of PKCε attenuates tumor formation by KRAS
Given the observation that PKCε and KRAS are dysregulated in a large
proportion of lung tumors, we asked whether loss of PKCε expression affects the
formation of KRAS-driven tumors. It has been reported that 12 to 16 weeks following
Ad-Cre administration, KRAS mice develop adenocarcinomas and die within 24 to 26
weeks after activation of the oncogene [42, 83, 92]. To evaluate the effects of PKCε
deletion in vivo, we randomized mice into three groups; KRASG12D;PKCε+/+,
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KRASG12D;PKCε+/- and KRASG12D;PKCε-/-. Mice were exposed to Ad-Cre at 6 to 8
weeks-old. Interestingly, KRAS-driven tumor formation in either PKCε heterozygous or
PKCε knockout mice was significantly reduced compared to KRAS mutant mice with
PKCε wild-type background. Therefore, loss of one PKCε allele was sufficient to
significantly affect lung tumor initiation (Fig. 4.3A). Neither the KRASG12D;PKCε+/- nor
the KRASG12D;PKCε-/- mice had incidence of extensive tumors. Indeed, 83.3 % of the
KRASG12D;PKCε+/+ mice developed extensive tumors, whereas only 53.8 % of the
KRASG12D;PKCε+/- or KRASG12D;PKCε-/- mice had small patchy areas of tumors.
Histological analysis also revealed that while KRASG12D;PKCε+/+ mice have multifocal
lung lesions, the lesions were markedly reduced in PKCε heterozygous mice and nearly
absent in a PKCε-null background (Fig. 4.3B).
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B

12 wk

12 wk

KRASG12D;PKC!+/+

KRASG12D;PKC!+/-

12 wk

KRASG12D;PKC!-/-

Figure 4.3 Genetic inhibition of PKCε impairs lung tumorigenesis by mutant KRAS
(A) Histological scoring system for lung tumors formed in the bitransgenic
G12D
-/+
G12D
-/G12D
KRAS
;PKCε and KRAS
;PKCε or KRAS
mice. 0 = minimal tumor seen; 1
= small patchy areas of tumors; 2 = extensive lung tumors. (B) Representative
G12D
G12D
-/+
G12D
-/histological sections of KRAS
, KRAS
;PKCε and KRAS
;PKCε lungs 12
weeks postinfection with Ad-Cre (5 × 105 PFU).
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Generation of pTRE-PKCε Mice
We have previously shown that PKCε is required for NSCLC cells growth and
tumorigenicity in nude mice [25, 26]. Studies have indicated that there is a causal
relationship between up-regulation of PKCε and cancer initiation in prostate and skin
cancer [6, 18]. We sought to investigate the phenotypic consequence of overexpressing
PKCε in the normal lung in vivo. As an approach we generated a transgenic mouse model
in which PKCε was specifically expressed in the lungs. In an inducible manner, PKCε
cDNA was inserted into a modified pTRE-tight promoter vector to generate a cassette
which contained the tetracycline-responsive element (TRE), minimal CMV promoter, Nterminal HA-tag and the PKCε gene. This construct allows turning transgene expression
“on” and “off" by doxycycline treatment. To validate the expression of PKCε, COS-1
cells were transiently co-transfected with pTRE-PKCε and pTetON plasmid. 24 h later,
cells were treated with increasing concentrations of doxycycline. We found a
concentration dependent elevation in PKCε expression in COS-1 cells (Fig. 4.4A). The
results were also further confirmed in MCF-7 cells that stably express the reverse
transcription transactivator (rtTA). In the presence of doxycycline, rtTA enabled the
expression of PKCε upon binding to the Tet-responsive element (Fig. 4.4B). Following in
vitro validations, linearized plasmid was microinjected into the pronucleus of fertilized
zygotes of S129/B6 mice and implanted into a pseudo-pregnant foster mother. Chimeric
mice were analyzed by Southern blot to select founders for transgenic lines. To detect the
PKCε transgene, an endogenous PKCε probe was used. As shown in Fig. 4.5, an

103

additional band was detected in DNA samples from the PKCε transgenic mice. This band
was absent in samples from wild-type C57BL/6 or mice the lack the transgene insertion.
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pTREtight-HA-PKC! + pTeton

-
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PKC!"
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B
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Figure 4.4 Validation of pTRE-PKCε vector construct before pronuclear
microinjection
(A) Cos-1 cells were co-transfected with pTet-On and pTRE-PKCε. The expression of
PKCε under the control of a tetracycline (Tet)-inducible promoter in response to different
concentrations of doxycycline was verified by Western blot. (B) MCF-7 Tet-On cells
were transfected with pTRE-PKCε and the expression of PKCε upon doxycycline
treatment was detected by Western blot.
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569

571
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pTRE-PKC!"

Wild-type
273
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239
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568

572

232

pTRE-PKC!"

Figure 4.5 Identification of transgenic founder lines
Genomic DNA was extracted from two wild-type and seven pTRE-PKCε transgenic mice
and digested overnight with BglII restriction enzyme. An endogenous PKCε sequence
was used as a probe and the number of pTRE-PKCε integrations in the genome was
assessed by Southern blot.
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4.3 Discussion
PKCε as a mediator of KRAS tumorigenesis
KRAS is a common mutation in many cancers, and the identification of mediators
of KRAS signaling is important to successfully develop therapeutic approaches. While
the oncogenic role of KRAS gene is widely established, the molecular effectors
responsible for its effects in lung cancer have not yet been fully elucidated. Here we
found that PKCε is required for KRAS-driven tumorigenesis in lungs. Genetic loss of
PKCε results in attenuated tumor formation upon activation of oncogenic KRAS in
mouse lungs. Notably, loss of one allele was sufficient to significantly inhibit KRASdependent lung tumorigenesis.
Lung-specific KRAS mutant mouse models have been widely used for
understanding the biology associated with KRAS-induced lung carcinogenesis. Three
different strategies have been previously used to express mutant KRAS for inducing lung
tumors in vivo. First, expression of a doxycycline-regulated KRASG12D transgene was
achieved using transgenic mice expressing reverse tetracycline transactivator transgene
under the control of surfactant factor C (SPC) promoter. In this model, tumor formation is
induced by doxycycline and the expression of KRASG12D can be turned “on” and “off” at
different time points [104]. The second strategy involves somatic recombination that
results in expression of KRASG12D. Although most tumors are formed in the lungs,
studies also reported tumors in other tissues [117]. The third model, LSL-KRASG12D,
which is the model we used in our studies, involves the expression of mutant KRAS upon
Cre-mediated removal of a stop codon sequence flanked by loxP. Cre-recombinase is
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delivered to the lungs either by an infection with adenoviral vector or by crossbreeding
with mice that express Cre under the control of an SPC promoter. All three models
ultimately result in the formation of lung tumors [83].
Using LSL-KRASG12D mice, several studies have identified downstream effectors
of KRAS in lung tumorigenesis. For example, deletion of NOS2 attenuated lung tumor
formation in mice expressing oncogenic KRAS [131]. The small GTPase Rac1 has also
been implicated in KRAS-induced lung cancer. KRASG12D;Rac1-/- mice showed delayed
tumor initiation, and the tumor to lung volume ratio was significantly reduced compared
to the Rac1 wild-type control mice [92]. Our studies suggest that PKCε is another key
effector in the initiation of KRAS-driven lung tumors. Twelve weeks after Ad-Cre
infection, KRAS mutant mice with PKCε heterozygous or knockout background had
reduced tumor incidence compared to KRASG12D;PKC+/+ mice. These results are
consistent with a tumor promoting role of PKCε in primary human NSCLC tumors.
Indeed, previous studies from our laboratory revealed that RNAi depletion of PKCε from
NSCLC cells results in significant inhibition of anchorage-dependent and independent
growth. Moreover, silencing PKCε in KRAS mutant NSCLC cells, such as A549, H441,
H358 and H322 cells reduced growth, proliferation and resulted in decreased metastatic
dissemination in xenograft models [25].
Our results raise a number of interesting questions for subsequent work, including
what role PKCε plays in maintenance of KRAS-induced lung tumors, as well as what
mechanisms and downstream effectors of PKCε mediate KRAS signaling. To establish
the important role of PKCε in tumor maintenance, we have initiated a survival
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experiment. In this experiment, 6-8 weeks old KRASG12D;PKCε+/+ and KRASG12D;PKCε+/mice were infected with Ad-Cre, and mice are being observed until they require
euthanasia due to tumor burden. We expect differential survival rates between mice with
PKCε wild-type and heterozygous backgrounds. Due to the tumorigenic role of PKCε in
lung cancer, the KRASG12D;PKCε-/+ mice are expected to live longer. However, we can
only speculate on the tumor burden differences at the time of death between the two
groups. In a study that analyzed the role of Rac1 using similar KRAS-driven mouse lung
tumor models, Rac1 was shown to delay tumor initiation. Additionally, KRAS mutant
mice in a Rac1 knockout background survived longer post-infection with Ad-Cre [92]. In
the KRASG12D;NOS2-/- model, mice had increased tumor latency, decreased tumor
growth, and longer survival time compared to the KRASG12D mice in NOS2+/+
background. At the time of death, NOS2 wild-type mice had 100 % incidence of at least
one carcinoma, while the incidence was slightly reduced to 89.5 % in NOS2 knockout
background [131]. Since PKCε has been implicated in the regulation of both Rac1 and
NOS2 in lung cancer and also has tumorigenic capacity in NSCLC cells in vitro, we
expect that KRASG12D; PKCε-/- mice, will display significant decrease in tumor size.
Several other effectors of PKCε could mediate its tumorigenic capacity. Studies from our
laboratory revealed that lesions that developed in mice overexpressing PKCε in the
prostate exhibited elevated Akt activation [18]. Additionally, depletion of Akt in mice
that harbor a latent activatible mutant KRAS (KRASLA2/+) resulted in reduced lung tumor
formation. Akt has also been implicated in chemically-induced lung carcinogenesis [76,
89]. The Erk/MAPK cascade and the Stat3 pathways are other potential mechanisms by
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which PKCε could drives tumor formation in the lungs as both are well-established PKCε
effectors in other models [5].

Inducible model for PKCε in mouse lungs
We aimed to inducibly overexpress PKCε in the lungs to recapitulate the scenario
observed in cancer patients. Additionally, by turning off the overexpression of PKCε, we
can determine if the kinase is important for the maintenance of lung tumors. The pTREPKCε mouse model we generated will hopefully results in the overexpression of PKCε
specifically in the lung when crossed with SPC-rtTA transgenic mice. SPC is exclusively
expressed in type II alveolar epithelia cells, which are sites of lung cancer occurrence.
The bitransgenic mice, SPC-rtTA-PKCε mice will express the reverse tetracycline
controlled transactivator (rtTA) protein under the control of the human SPC promoter.
rtTA then binds to the promoter of the tetracycline element (pTRE) and drives the
expression of PKCε in the presence of doxycycline [42, 83]. An additional advantage of
the pTRE-PKCε mice is that they can be used to generate other tissue-specific transgenic
models by crossing with appropriate mouse models that direct transgene expression in
different cell types.
As we are currently optimizing the PCR assay for genotyping the pTRE-PKCε
mice, we can only speculate about the phenotypic outcome of the SPC-rtTA-PKCε mice
at this stage. Previously our lab has generated transgenic mice that overexpress PKCε in
the mouse prostate under the control of the probasin promoter. Overexpression of PKCε
in these transgenic mice led to the development of preneoplastic lesions, which
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progressed to invasive adenocarcinoma of the prostate in a PTEN-deficient background.
Similar results are expected from the lung-specific PKCε mice where overexpression of
PKCε may lead to precancerous lesions of the lung. To develop adenocarcinoma of the
lungs, PKCε may require cooperation from other genetic alterations such as KRAS or
EGFR mutations. Similarly, the requirement of carcinogens for PKCε-dependent tumor
progression from hyperplasia to carcinoma was seen in skin-specific PKCε
overexpressing mice. Although these mice developed hyperplasia, squamous cell
carcinoma was induced 12 weeks after combinational treatment with DMBA and a
phorbol ester [6].
Summary
Here we have presented evidence showing the requirement of PKCε for KRAS
induced mouse lung tumors using a bitransgenic KRASG12D;PKCε-/- mouse model
generated in our lab. We have also generated a pTRE-PKCε mouse model that can be
used for lung-specific overexpression of PKCε in an inducible manner. These animal
models will enable us to elucidate the diverse roles PKCε plays in the initiation and
maintenance of lung tumors. Additionally, the lung-specific PKCε overexpressing mice
will enable us to delineate oncogenic alteration that cooperate with PKCε to promote
lung tumors in vivo.
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4.4 Material and Methods
Mice Strains
PKCε -/+ mice were developed in the laboratory of Dr. Robert Messing (UCSF) as
described previously [91]. Briefly, a mouse genomic PKCε sequence with depletion of
the start codon was inserted to a recombination vector. The linearized construct was
electroporated into embryonic stem cells. Clones were selected in culture in the presence
of hygromycin and neomycin and analyzed for predicted homologous integration.
Recombinant clones was then microinjected into blastocysts and implanted in pseudofertilized mice. The chimeric mice were crossed with C57BL/6 WT mice. LSL-KrasG12D
heterozygous mice (B6.129-Krastm4Tyj), originally developed by Dr. Tyler JackS, was
obtained from Jackson laboratories. Briefly, the G12D mutation was inserted in exon 1 of
the KRAS gene followed by insertion of loxP-flanked stop element in intron 1, upstream
of the mutation. The linearized vector was electroporated into embryonic stem cells. The
chimeric mice was backcrossed to C57BL/6 for more than 10 generations by The Jackson
Laboratory.

KRASG12D and PKCε mutant mice genotyping
To genotype mice, genomic DNA was extracted from tail clippings and analyzed
by PCR using the Hot Start PCR kit from New England Biolabs. The sequence of PCR
primers for confirmation of KRASG12D and heterozygous or knockout PKCε backgrounds
were provided from the Jackson Laboratory and the Messing laboratory respectively.
PCR primers for confirmation of KRASG12D were 5′-GTCGACAAGCTCATGCGGGTG,
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5′-CCTT

TACAAGCGCACGCAGACTGTAG

and

5′-

AGCTAGCCACCATGGCTTGAGTA AGTCTGCA. For PKCε the primers were 5′ACATGCAGAATGAGTACCGG-3′, 5′-TCAACATCTCCTGGTGGAAC-3′ and 5′AATATGCGAAGTGGACCTCG-3′.

Ad-Cre infections
Recombinant adenovirus encoding Cre recombinase (Ad-Cre) was purchased
from the University of Pennsylvania Gene Transfer Vector Core. 6 to 8 week-old mice
were infected intranasally with 100 µl of saline containing 3 × 1010 PFU Ad-Cre. 20
minutes prior to injection of 0.5 µl of 2 mol/l CaCl2 was added to improve gene transfer
to airway epithelia. Before injections mice were anesthetized with ketamine (100mg/kg).

Histology and immunohistochemistry
For histological evaluation, whole lungs were manually inflated and fixed with
10% formalin and then embedded in paraffin blocks. Longitudinal sections of lung were
stained with hematoxylin and eosin (H&E) and evaluated by Dr. Steven Albelda
(University of Pennsylvania). Tumors were given histologic scores as 0 (minimal tumors
seen), 1 (small patchy areas of tumors), and 2 (extensive lung tumors).
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pTRE-PKCε vector construction
cDNA encoding for PKCε was excised from the pB.PKCε vector and ligated into
a pTRE-tight vector using T4 DNA ligase (Life Technologies). Initially, the pB.PKCε
vector was modified by inserting a linker containing MluI, ATG and HA epitope using
restriction enzymes NotI and XhoI (New England Biolabs). This modification generated a
sequence coding for Mlu-ATG-HA-XhoI- PKCε- Mlu in the pB.PKCε vector. For the
pTRE-tight vector, a stop codon was added flanked with Mlu and NotI restriction sites.
Finally, the ATG-HA-PKCε was released from the pB.PKCε vector by digesting with
Mlu and ligated into the pTRE-tight vector. pTRE-PKCε plasmid was transformed into
E.coli (DH5α) and was purified using QIAprep maxi kit (Qiagen) according to the
manufacturer's instructions. The purified plasmid was digested with the restriction
enzyme Mlu to confirm isolated clones for cDNA insert and the plasmid vector. Clones
with the correct orientation of insertion were selected after sequencing and verified by
vector mapping using various enzymes. For in vitro validation of PKCε expression, Cos1 cells (1 × 105 cells/well in 12-well plates) were transfected with 0.1 µg/µL of pTet-On
and 0.4 µg/µL of pTRE-PKCε using Lipofectamine2000 (Invitrogen). After 24 h, cells
were treated with doxycycline (Clontech) at concentrations of 0.1, 1, 5 and 10 µg/µL.
The expression of PKCε was also validated by transfecting pTRE-PKCε. pTRE-PKCε
was digested and linearized by PciI and bcgI to remove unnecessary backbone of the
pTRE-tight vector and was submitted to the Wistar Institute Transgenic Mouse Facility
for pronuclear injection. Chimeric mice were generated in S129/B6 background.
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Southern blot
Genomic DNA was digested overnight with BglII and subjected to electrophoresis
on a 0.7 % agarose gel. DNA was transferred to Zeta-Probe GT (Biorad) nylon
membrane. The membrane was UV crosslinked and prehybridized in ExpressHyb
solution (Clontech) containing salmon sperm DNA at 600 C. The 239 base pair fragment
of the plasmid pB.PKCε digested with PstI and BamHI was used as probe, radiolabeled
using Exo (-) Klenow DNA polymerase (Biorad) and hybridized with DNA on the
membrane in ExpressHyb solution overnight at 600 C. The membrane was exposed to Xray film and visualized by autoradiography.
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CHAPTER 5: Conclusions and Future Directions

115

This thesis work established the importance of PKC isozymes in the initiation and
progression of lung cancer. PKC isozymes were found to regulate drug resistance, NF-κΒ
pathway activation, and KRAS-driven lung tumorigenesis. We showed for the first time
that PKC isozymes are implicated in the selective and adaptive mechanisms that are
responsible for acquired resistance to molecular-targeted therapy. Our results indicate
altered expression of PKCα and PKCδ in NSCLC cells resistant to erlotinib.
Furthermore, overexpression of PKCα and down-regulation of PKCδ are required to
induce erlotinib resistance. We also provided data showing that PKCα is essential for the
maintenance of mesenchymal phenotype observed in erlotinib-resistant cells. Similar to
drug resistance, inflammation is another key factor that contributes to the progression of
lung cancer. Our data indicate that PKCα is a positive regulator of NF-κΒ signals in
NSCLC cells, suggesting its role in the promotion of inflammation. PKCα regulates key
steps of the canonical NF-κΒ pathway activation, including IκΒα phosphorylation, NFκΒ promoter activity, NF-κΒ DNA binding, and expression of NF-κΒ responsive genes
involved in cell survival, motility, angiogenesis, and inflammation. The role of PKCs in
lung cancer is not limited to disease progression, as we also identified the requirement for
another PKC isozyme, PKCε, in the development of KRAS-driven lung tumor formation.
By generating a mouse model that expresses mutant KRAS in a null PKCε background,
we demonstrated that PKCε is required for KRAS-driven lung tumorigenesis.
Resistance to therapy has been a major hurdle in lung cancer treatment.
Identification of mechanisms associated with acquired resistance presents a strategy to
overcome this hurdle. Our data in Chapter 2 provides compelling evidence for the use of
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PKCα inhibitors in combination with erlotinib. Inhibition of PKCα using
pharmacological inhibitors or with RNA interference significantly enhanced the
sensitivity of NSCLC cells to erlotinib. PKCα was also shown to modulate its effect on
erlotinib sensitivity, in part, by regulating the expression of PKCδ. Overexpression of
PKCα in erlotinib-sensitive cells led to down-regulation of PKCδ, suggesting that the
low levels of PKCδ seen in the erlotinib-resistant cells could have been driven by the
overexpression in PKCα. Furthermore, reconstitution of PKCδ in erlotinib-resistant cells
enhanced their sensitivity to erlotinib, thus underscoring the importance of PKCδ downregulation in acquired resistance to erlotinib therapy.
Chapter 2 of this thesis also provides insight into how PKCα could be implicated
in the selective mechanism that induces resistance to erlotinib. As previously
documented, erlotinib-resistant cells have elevated expression of genes associated with
EMT and display morphological changes that are reminiscent of the mesenchymal
phenotype [212]. Our results demonstrated that although PKCα does not affect the
expression of the epithelial marker E-cadherin, it regulates the expression of genes
implicated in the induction of the mesenchymal phenotype, such as vimentin and Snail.
The mechanisms through which PKCα acts to regulate the expression of genes associated
with mesenchymal phenotype in lung cancer cells are yet to be determined. Recent
studies in breast cancer revealed that PKCα preferentially supports the maintenance of
mesenchymal cell state through its regulation of the transcription factor FRA1 (Fosrelated antigen 1). Whether a similar mechanism operates in lung cancer remains to be
determined. A potential transcription factor that could be involved in PKCα-dependent
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expression of EMT markers in NSCLC cells is NF-κB. Studies have identified known
EMT marker genes such as vimentin, Snail and Zeb2 as target genes of NF-κB in several
cancer types [9, 33, 103, 200] and in Chapter 3 of this thesis, we have established that
PKCα-mediated regulation of NF-κB is required for the expression of NF-κB responsive
genes in NSCLC cells. It would be important to determine if PKCα-dependent NF-κB
activation is required for the transcription of vimentin, Snail, Twist and Zeb2 in erlotinibresistant cells.
Our results also indicate that a subpopulation of erlotinib naive cells that express
the mesenchymal surface marker CD44 exhibit higher levels of PKCα expression
compared to the cell population where CD44 is absent. It would be interesting to see if
stable overexpression of PKCα could increase the expression of CD44 as well as the
expression of genes associated with the mesenchymal phenotype. Several studies have
shown that cells undergoing EMT become aggressive and develop resistance to therapies.
Conversely, EMT can be induced as a consequence of exposure to therapeutic drugs
[182]. Our model of erlotinib-resistant cells presents yet a different mechanism for drug
resistance where EMT and drug resistance co-exist, but do not have a causal relationship.
As previously reported [212], depletion of genes associated with the mesenchymal
phenotype did not alter the sensitivity to erlotinib, and erlotinib naive cells possess a
subpopulation that already underwent EMT.
The cells we used as a model for erlotinib resistance have high levels of TGF-β
compared to the parental erlotinib-sensitive cells. TGF-β signaling is required and
sufficient for the induction of erlotinib resistance and EMT in erlotinib-resistant cells and
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our results revealed that TGF-β signaling drives the expression of PKCα in these cells.
To assert the explicit dependence of PKCα expression on TGF-β, it is important to
determine if inhibiting TGF-β levels in erlotinib-resistant cells to the level observed in
the parental erlotinib-sensitive cells could decrease PKCα expression. Although the
mechanism by which overexpression of PKCα mediates erlotinib resistance and EMT
remains to be determined, we propose a model implicating PKCα in the transition from
epithelial to mesenchymal cells and drug resistance in NSCLC cells (Fig. 5.1).
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Figure 5.1 Proposed model for PKCα-mediated erlotinib resistance in NSCLC cells
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In Chapter 3, we demonstrated an additional role of PKCα in cellular processes
implicated in lung cancer progression. PKCα regulates the activation of the NF-κΒ
pathway in response to IL-1β. Inhibition of PKCα resulted in decreased IκΒα
phosphorylation, indicating that it regulates the canonical NF-κΒ pathway. The effect
was further supported by the observation that PKCα inhibition blocks NF-κΒ
translocation and DNA binding. Activation of NF-κΒ is required for the induction of
genes in response to IL-1β including pro-inflammatory genes. Our findings indicate that
PKCα-mediated activation of NF-κΒ by IL-1β results in up-regulation of NF-κΒresponsive genes such as MMP9, COX-2 and IL-8. These findings suggest that PKCα
could play an important role in promoting lung cancer progression that results from
chronic inflammation.
Future experiments must be done to identify the mechanism for PKCα-mediated
activation of NF-κB in response to IL-1β. PKCs translocates from the cytosol to the
plasma membrane upon activation. We can use real-time microscopy to assess whether
IL-1β could induce changes in the subcellular localization of PKCα using a GFP-fused
PKCα construct. If PKCα translocates to the plasma membrane upon IL-1β stimulation,
it could potentially associate with IL-1R, the receptor for IL-1β. Indeed, an analogous
mechanism was recently discovered by our laboratory for PKCε and the receptor for
TNFα [54]. Immunoprecipitation of IL-1R from H460 cells will show whether
endogenous PKCα coimmunoprecipitates with this receptor. If PKCα associates with the
IL-1R, we speculate that IL-1β treatment will enhance that association. PKCα could also
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be involved in the activation of NF-κB through phosphorylation of IKKs or
phosphorylation of the RelA subunit important for the localization of the p50/RelA dimer
to the nucleus. In vitro kinase assay could be utilized to determine if PKCα directly
phosphorylates the IKK complex or the RelA subunit in NSCLC cells. These potential
mechanisms are summarized in Fig. 5.2.
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Figure 5.2 Proposed model for the regulation of the canonical NF-κB pathway by
PKCα in NSCLC cells.
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The work presented in this thesis also highlights the importance of PKC isozymes
in lung cancer initiation. Previous studies from our lab established a key role for PKCε in
lung cancer progression in KRAS mutant NSCLC cell lines and xenograft models [25,
26]. In Chapter 4, we further demonstrated the requirement of PKCε for KRAS-induced
lung tumor formation in a mouse model where mutant KRAS is expressed in a PKCε-null
background. Indeed, genetic ablation of PKCε significantly attenuated tumor formation in
KRAS mutant mice. Future experiments include determining what role PKCε plays in the
maintenance of KRAS-induced lung tumors, as well as what mechanisms and
downstream effectors of PKCε mediate KRAS signaling.
It would also be important to determine whether overexpression of PKCε
accelerates KRAS-driven lung tumor formation, and if by itself, is sufficient to induce
precancerous or cancerous lesions in the lungs. We generated a mouse model that
specifically expresses PKCε in the lungs when crossed with SPC-rtTA transgenic mice.
Future experiments could use this model to generate KRAS mutant mice that overexpress
PKCε in the lungs. We speculate that overexpression of PKCε in the lungs leads to the
formation of preneoplastic and neoplastic lesions. On the basis of our preliminary results
from bitransgenic KRASG12D;PKCε-/- mice, we also expect that overexpression of PKCε
accelerates tumor formation and increases tumor incidence in the lungs.
In conclusion, the data presented in this thesis has further established the
significance of PKC isozymes in lung cancer development. Our work has identified the
requirement of PKCα in selective and adaptive processes that result in the loss of
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erlotinib sensitivity. We further established the importance of PKCα in the progression of
NSCLC by demonstrating its regulation of the NF-κΒ pathway. Our results support the
use of PKCα inhibitors for lung cancer patients with indications of TKI resistance and
hyperactivation of the NF-κB pathway. Additionally, our work gives insights into the role
of PKC isozymes in the initiation of lung cancer. We identified the requirement of
PKCε signaling in KRAS-driven lung tumor formation. Pharmaceutical companies have
been interested in the development of PKCε specific inhibitors for cancer treatment [38]
and our results corroborate that PKCε specific inhibitors can be effective candidates for
lung cancer prevention and treatment.
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